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ABSTRACT 
 
S-nitrosation is the covalent attachment of nitric oxide (NO) moiety to cysteine thiol side 
chain. This reversible modification represents an important mechanism of post-
translational regulation for a large number of proteins. In the cellular environment, S-
nitrosoglutathione (GSNO) can transfer its NO group to reactive cysteine residues within 
proteins via transnitrosation reactions. Similarly, S-nitrosated protein can transfer its NO 
moiety to reduced glutathione (GSH). Due to the existence of this equilibrium, the GSNO 
metabolizing enzyme GSNO reductase (GSNOR) indirectly drives protein de-nitrosation. 
To date, aberrant GSNOR activity has been implicated in a large spectrum of human 
diseases. In this dissertation, we report the synthesis and characterization of O-
aminobenzoyl-S-nitrosoglutathione (OAbz-GSNO), a novel fluorogenic substrate for 
GSNOR. OAbz-GSNO reduction mediated by GSNOR results in significant increases in 
fluorescence; and this increase in fluorescence is attenuated by GSNOR inhibitor 
treatment. In addition, OAbz-GSNO is cell membrane permeable and can be used to 
monitor endogenous GSNOR activity in cultured cells. Overall, our work demonstrates 
that OAbz-GSNO is a useful tool for assessing GSNOR activity, both in vitro and in 
cells. Site-directed mutagenesis and kinetic studies conducted using recombinant GSNOR 
suggest acetylation of Lys101 negatively affects enzyme activity; while computational 
simulations uncovered a putative allosteric GSNO binding site. We have experimental 
evidence supporting our model that GSNO binding to this allosteric site enhances 
GSNOR activity. Both lysine acetylation and allosteric substrate binding represent 
potential mechanisms involved in the post-translation regulation of GSNOR activity. 
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Neutral sphingomyelinase II (NSMase II) is a mediator of cellular stress response. 
It catalyzes the hydrolysis of plasma membrane sphingomyelin to generate bioactive 
ceramide and phosphocholine. This project looks into whether chronic cortisol exposure 
(as a stressor) affects NSMase II expression/activity. Experimental results demonstrate 
exposure to cortisol leads to increased cell size, but NSMase II expression and activity 
are unaffected. However, NSMase II over-expressing cells appear to have less cholesterol 
in the plasma membrane. Since cholesterol is important for the formation of lipid rafts, 
these finding suggest that in addition to ceramide generation, modulation of plasma 
membrane cholesterol content may represent an alternative mechanism by which 
NSMase II exerts its biological effects.  
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CHAPTER 1 
General Introduction 
  
 2 
 
1.1 Nitric Oxide 
Nitric oxide (NO) is a diatomic free radical gasotransmitter. In the 1980s, multiple 
research groups independently identified NO as the endothelium derived relaxing factor 
responsible for eliciting vascular smooth muscle relaxation [1-4]. Since then, the field of 
NO biochemistry has expanded significantly and NO is now a well-established signaling 
molecule known to affect a vast number of physiological processes. For instance, NO is 
involved in the control of vascular tone [5-7] and blood pressure [8, 9]; promotes 
angiogenesis [10]; and mediates neurotransmission [11, 12], immune response [13, 14], 
as well as wound healing [15].  
 1.1.1 NO Synthases 
Endogenous NO is enzymatically synthesized in mammalian tissues by 3 isoforms of 
nitric oxide synthase (NOS; EC 1.14.13.39). The isoforms have been named neuronal 
NOS (nNOS, NOS 1), inducible NOS (iNOS, NOS 2) and endothelial NOS (eNOS, NOS 
3) based on their tissue of constitutive expression or basal level of activity. All NOS 
isoforms function as homodimers and catalyze the oxidation of L-arginine to L-citrulline 
and NO [16]. Molecular oxygen and reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) are co-substrates for this reaction. The overall reaction utilizes 2 
mol of O2 and 1.5 mol of NADPH for every mol of NO produced [17, 18]. In addition to 
substrates, NOS catalyzed NO production requires a number of cofactors/coenzymes, 
including flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), 
tetrahydrobiopterin (BH4) and calmodulin [18]. 
 nNOS is constitutively expressed in the neurons of the central and peripheral 
nervous system, as well as epithelial cells of various organs [19, 20]. Its activity is 
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regulated by intracellular Ca2+ levels through calmodulin binding. nNOS derived NO 
mediates synaptic plasticity, which affects complex physiological functions such as 
neurogenesis, learning and memory formation [21, 22]. nNOS is also involved in the 
central regulation of blood pressure [23, 24]. iNOS expression is usually induced by 
agents such as bacterial lipopolysaccharide and cytokines. Once expressed, iNOS 
produces large amounts of NO and its activity is not affected by Ca2+. In macrophages, 
NO produced by iNOS contributes to host immune defense by exerting cytotoxic effects 
on pathogens [14, 19]. eNOS is mainly expressed in endothelial cells and its activity is 
regulated by a number of factors, including intracellular Ca2+ concentration and fluid 
shear stress [25]. NO produced by endothelial cells results in vasorelaxation; and protects 
blood vessels from thrombosis by inhibiting platelet aggregation and adhesion [26, 27].  
 1.1.2 Mechanisms of NO Signaling 
Multiple mechanisms have been identified for NO-mediated signaling (Figure 1.1.2-1). 
Canonical signaling involves NO activating soluble guanylate cyclase (sGC) by binding 
to its heme iron [28]. Once activated, sGC converts guanosine triphosphate (GTP) to 
cyclic guanosine monophosphate (cGMP). Subsequent down-stream effects are mediated 
by cGMP-dependent protein kinases [29]. Within the mitochondria, NO competes with 
O2 for binding to cytochrome c oxidase (CcO), the terminal enzyme of the electron 
transport chain [30]. NO binding inhibits CcO. This inhibition is reversible and can 
initiate biochemical events such as reactive oxygen species generation and AMP-kinase 
activation [31]. NO can also signal through covalent post-translational modifications of 
target proteins. These modifications include S-nitrosation, S-glutathionylation and 
 4 
 
tyrosine nitration [29].  The modification most relevant to this dissertation is S-
nitrosation, which is discussed in detail in the next section.  
 
 
Figure 1.1.2-1 Overview of nitric oxide signaling mechanisms  
Classical signaling involves nitric oxide (NO) production by nitric oxide synthase (NOS) 
and the activation of soluble guanylate cyclase (sGC). Less classical signaling is based on 
NO mediated inhibition of cytochrome c oxidase (CcO) in the mitochondria. Non-
classical pathways include the formation of post-translational modifications. Image from: 
Martinez-Ruiz et al. (2011). "Nitric oxide signaling: classical, less classical, and non 
classical mechanisms." Free Radical Biology and Medicine 51(1): 17-29. With 
permission. 
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1.2 Protein S-nitrosation 
S-nitrosation refers to the covalent attachment of NO derived nitroso group to a cysteine 
thiol, which results in the formation of S-nitrosothiol (SNO). This modification is also 
commonly known as S-nitrosylation. Chemically, the term ‘nitrosation’ describes the 
addition of nitrosonium cation (NO+) to a nucleophilic group such as thiolate; whereas 
‘nitrosylation’ refers to direct addition of NO to a reactant [32]. However, when the 
mechanism of SNO formation is unknown or ambiguous, questions arise as to which term 
should be used. Some researchers have adopted ‘S-nitrosylation’ as a general biological 
term to describe the formation of SNO species regardless of mechanism (analogous to 
phosphorylation or acetylation) [33], while others feel this analogy is unwarranted since 
‘nitrosylation’ carries mechanistic implications and NO alone cannot react with thiols or 
thiolates under physiological conditions [32]. In this dissertation, the term ‘S-nitrosation’ 
will be used to describe this thiol modification and to highlight the involvement of NO+.  
Cysteine residues within proteins can be modified by S-nitrosation. This post-
translational modification is reversible and constitutes an important mechanism by which 
NO exerts its biological effects (Figure 1.1.2-1) [29]. Over the years, there is increasing 
research evidence suggesting that S-nitrosation participates in both normal physiology 
and in the pathogenesis for a large spectrum of human diseases [34]. Aberrant protein S-
nitrosation typically involves hypo- or hyper-S-nitrosation of specific targets. This could 
result from changes in the expression, localization, and/or activity of enzymes such as 
NOS, which generates NO from L-arginine, and S-nitrosoglutathione reductase 
(GSNOR), which promotes protein de-nitrosation by metabolizing the transnitrosating 
agent S-nitrosoglutathione (GSNO).  
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Evidence to date indicates that unlike other post-translational modifications, S-
nitrosation of proteins is not directly catalyzed by enzymes. Instead, signaling specificity 
is largely dictated by the chemical reactivity between the nitrosating agent and target 
cysteine thiol [35]. Particular protein microenvironments lead to increased reactivity for 
certain cysteine residues, thus favouring their modification. Several attempts have been 
made to describe a putative “nitrosation motif” [36-38]. However, since S-nitrosation 
could occur via multiple mechanisms [39, 40], which are still not fully understood, the 
existence of a single consensus motif seems unlikely. 
As previously mentioned, NO alone does not react with thiols or thiolates under 
physiological conditions. For S-nitrosation to occur, NO needs to be first oxidized to 
higher oxides of nitrogen such as nitrogen dioxide (NO2) or dinitrogen trioxide (N2O3). 
Of the potential S-nitrosating species, N2O3 could react with thiols directly according to 
Equation 1.2-1. However, questions have been raised regarding the slow kinetics of 
initial NO oxidation under physiological NO and O2 concentrations [41-43].  
(1.2-1)  RS- + N2O3  RSNO + NO2
- 
NOS activation effectively increases local NO concentrations, potentially favoring the 
generation of S-nitrosating species. In this context, co-localization or direct interaction 
with active NOS can positively influence S-nitrosation [44, 45]. Accelerated NO 
oxidation by O2 has also been reported in hydrophobic compartments such as biological 
membranes [46], further implicating the importance of subcellular compartmentalization 
in controlling the occurrence and specificity of S-nitrosation.  
An alternative mechanism proposed for SNO formation involves NO reacting 
with a reduced thiol to form a radical intermediate. Then, in the presence of an electron 
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acceptor (such as O2 ) SNO and superoxide are formed [47]. In 1996, Schmidt and 
colleagues attempted to measure NOS-produced NO radical directly (rather than nitrate 
or nitrite) and reported that NOS did not yield detectable NO unless superoxide 
dismutase (SOD) was also present. Based on experimental findings, this group concluded 
NOS activity produces NO- as an NO precursor, which is acted upon by SOD to generate 
NO. In addition, when both SOD and GSH are present, the formation of GSNO was 
detected [48]. These observations provided strong evidence for enzyme mediated SNO 
formation. 
Proteins can become S-nitrosated via transnitrosation. These reactions are fully 
reversible and often involve low molecular weight SNO such as GSNO (Equation 1.2-2).  
 (1.2-2)  RS- + GSNO ↔ RSNO + GS- 
Interestingly, ferric cytochrome c can promote GSNO formation; the proposed 
mechanism involves initial weak binding between GSH and cytochrome c, followed by 
reaction with NO to generate GSNO and ferrous cytochrome c [49]. This increase in 
GSNO levels in turn promotes S-nitrosation of proteins [50]. In addition to cytochrome c, 
dinitrosyl iron complexes have also been shown to enhance S-nitrosation of proteins 
through transnitrosation [51, 52].  
More recently, de-nitrosation pathways have emerged as another important 
regulatory mechanism for signaling through S-nitrosation [53]. Due to the reversible 
nature of transnitrosation, increases in cellular glutathione (GSH), as well as decreased 
levels of GSNO, both contribute to protein de-nitrosation. A number of enzyme systems 
(including GSNOR [54], superoxide dismutase [55], glutathione peroxidase [56], 
thioredoxin [57], and carbonyl reductase 1 [58]) have been proposed to be involved in 
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GSNO metabolism in humans. Of these enzymes, only GSNOR and carbonyl reductase 1 
are capable of irreversibly removing the NO equivalents stored in GSNO, while kinetic 
comparisons suggest GSNOR is the most efficient GSNO-metabolizing enzyme [59].  
1.3 S-nitrosoglutathione Reductase 
 1.3.1 From Class III Alcohol Dehydrogenase to S-nitrosoglutathione Reductase 
Mammalian alcohol dehydrogenase (ADH) belongs to the protein superfamily of medium 
chain dehydrogenases / reductases [60] and consists of at least six known classes based 
on primary structure and function [61]. ADH is the major enzyme system responsible for 
ethanol metabolism (Reaction 1.3.1-1) and can also catalyze the oxidation of other 
primary and secondary alcohols using nicotinamide adenine dinucleotide (NAD+) as the 
co-factor. 
 
Reaction 1.3.1-1 ADH catalyzed ethanol oxidation, forming acetaldehyde as the product. 
 
Class III alcohol dehydrogenase (ADH III) was first isolated and purified to 
homogeneity from the human liver in the 1980s [62, 63]. Early studies revealed that even 
though ADH III resembles previously discovered ADH isozymes in terms of molecular 
weight, metal ion binding, and optimal pH for catalytic activity, it differs remarkably 
from other known ADH members by exhibiting very poor activity towards ethanol, with 
an apparent Km of more than 2 M [62, 63].  Instead, ADH III prefers long chain primary 
alcohols and aldehydes as substrates [63, 64]. In 1989, Koivusalo et al. reported evidence 
that ADH III is actually homologous to the ubiquitous cytosolic enzyme formaldehyde 
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dehydrogenase which catalyzes the oxidation of S-hydroxymethylglutathione (HMGSH) 
to S-formylglutathione (Reaction 1.3.1-2) [65, 66]. The adduct HMGSH is formed 
spontaneously between formaldehyde and glutathione. By metabolizing HMGSH, ADH-
III was noted as an important component in formaldehyde detoxification [67].  
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Reaction 1.3.1-2 Formaldehyde is a highly toxic metabolite. In the presence of GSH, it 
forms the adduct HMGSH, which in turn is converted to S-formylglutathione by ADH III 
using NAD+ as the cofactor.  
 
Formaldehyde GSH 
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Later in 1998, Jensen and colleagues discovered that in addition to activity 
towards HMGSH, ADH III can efficiently catalyze the NADH-dependent reduction of 
GSNO [54]. As a result, this enzyme is sometimes referred to as GSNO reductase 
(GSNOR). Since GSNO is considered to be an endogenous mediator of NO signaling, 
this enzyme with GSNO reductase activity rapidly caught the attention of researchers in 
the NO signaling field.  
Many different nomenclatures (including ADH III, chi-chi alcohol 
dehydrogenase, glutathione-dependent formaldehyde dehydrogenase, and GSNO 
reductase) have been used in literature to describe this enzyme. In all subsequent sections 
of this dissertation, the name GSNOR will be consistently used to refer to this enzyme. 
1.3.2 Regulation of GSNOR Gene Expression 
In humans, there are 7 identified ADH genes located in a cluster on chromosome 4q. 
GSNOR is encoded by the gene ADH5, which consists of 9 exons. The 5’ untranslated 
region of ADH5 is GC rich and lacks a TATA or CAAT box; both of which are 
characteristics of housekeeping genes with ubiquitous expression [68]. Several research 
groups have looked into the regulation of ADH5 expression. A study by Kwon et al. 
revealed two specificity protein 1 (Sp1) binding sites critical for transcription initiation, 
while competitive binding by Sp3 or Sp4 represses ADH5 expression [69]. Interestingly, 
high levels of GSNO can decrease/inhibit Sp3 binding on the cystic fibrosis 
transmembrane conductance regulatory gene (CFTR) [70]. If GSNO also negatively 
affects Sp3 binding on ADH5, this could represent a regulatory feedback loop for 
GSNOR such that when GSNO concentration is high, Sp3 binding is inhibited to favour 
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Sp1 binding and ADH5 transcription; which in turn leads to increased GSNOR 
expression and increased GSNO metabolism until homeostasis is restored.  
In addition to Sp binding sites, ADH5 also contains an up-stream open reading 
frame with two possible AUG start codons. These up-stream open reading frames are an 
unusual feature in mammalian mRNAs and have been postulated to play a regulatory role 
as mutations at one or both of these up-stream AUG codons led to an increase in ADH5 
gene expression [71].  
 1.3.3 GSNOR Protein Structure 
Crystal structure of human GSNOR shows that it is a homodimer with 40 kDa subunits 
(Figure 1.3.3-1). Each subunit contains a catalytic domain and a coenzyme binding 
domain. The catalytic domain is completely solvent exposed and displays a semi-open 
conformation. This conformation provides the structural basis for GSNOR’s ability to 
accommodate larger substrates such as HMGSH and GSNO [72]. Mutagenesis studies 
suggest that the positively charged Arg115 is critical for HMGSH binding. When this 
residue is changed to Asp, catalytic efficiency for HMGSH oxidation decreases 
significantly [73]. In addition to Arg115, HMGSH also interacts with the highly 
conserved Thr47, Asp56 and Glu58 [74]. Whether the same residues facilitate the binding 
of GSNO is currently unknown.  
Similar to all other members of the ADH family, GSNOR is a zinc containing 
enzyme. Each subunit contains one catalytic zinc, as well as one structural zinc (Figure 
1.3.3-1). The catalytic zinc is located within the active site and acts as a Lewis acid 
during catalysis; while the structural zinc is critical for the maintenance of proper protein 
structure.  
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A number of studies have looked at the coordination environment of the active 
site zinc [74-77]. In the apoenzyme, the active site zinc is coordinated by Cys45, His67, 
Cys174 and a water molecule. Upon coenzyme binding, the active site zinc is displaced 
towards Glu68. This displacement decreases interaction with the solvent water molecule 
and has been postulated to facilitate ligand exchange at the active site [76]. 
The structural zinc is coordinated by four closely spaced cysteine residues 
(Cys97, Cys100, Cys103 and Cys111). This coordination pattern is highly conserved for 
all classes of ADH [78]. Even though the structural zinc does not directly participate in 
catalysis, it is still a critical feature and mutating any one of these four cysteine residues 
results in inactive and unstable enzyme [79]. Although the sensitivity of these cysteine 
residues towards oxidation has not yet being evaluated, it is feasible that the peptide 
microenvironment contributes to the maintenance of proper oxidation state. 
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Figure 1.3.3-1 GSNOR protein structure  
Left: dimeric structure of GSNOR with the monomers shown in green and yellow. Right: 
close up view of the active site. Image from: Staab et al. (2008). "Medium- and short-
chain dehydrogenase/reductase gene and protein families: Dual functions of alcohol 
dehydrogenase 3: implications with focus on formaldehyde dehydrogenase and S-
nitrosoglutathione reductase activities." Cellular and Molecular Life Sciences 65(24): 
3950-3960. With permission.  
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1.3.4 Functions of GSNOR 
GSNOR is highly conserved in both prokaryotic and eukaryotic organisms [80-83], and is 
ubiquitously expressed in all human tissues studied [84, 85]. This universal pattern of 
expression suggests that GSNOR likely performs important cellular functions. Over the 
years, numerous studies have presented evidence that GSNOR participates in a number of 
pathways, ranging from first-pass ethanol metabolism in the gastric lumen following 
ethanol consumption [86], to ω-hydroxy fatty acid oxidation [54, 65], formaldehyde 
detoxification [67, 87-89], and GSNO metabolism [54, 90-93]. Two of the better 
characterized activities of GSNOR are glutathione-dependent formaldehyde oxidation 
(Reaction 1.3.1-2), and NADH-dependent GSNO reduction (Figure 1.3.4-1).  
The glutathione-dependent formaldehyde dehydrogenase (FDH) activity is an 
important mechanism for the elimination of formaldehyde, which is a classified 
carcinogen due to its high reactivity towards DNA and proteins [94-96]. Sources of 
cellular formaldehyde include both endogenous metabolism and environmental exposure 
[97-100].  Under physiological conditions, formaldehyde readily reacts with glutathione 
(GSH) to form HMGSH [87], which is in turn converted to S-formylglutathione by 
GSNOR, using NAD+ as the cofactor. Finally, S-formylglutathione is broken down to 
glutathione and the less reactive formate by S-formylglutathione hydrolase [101, 102]. 
Immunocytochemical studies demonstrate that GSNOR is localized to the cytoplasm as 
well as over condensed chromatin in the nucleus [103]. The nuclear localization of 
GSNOR supports its role in protecting DNA from formaldehyde toxicity.  
In addition to GSNOR, there are enzymes (ALDH1A1 and ALDH2 in humans) 
from the aldehyde dehydrogenase superfamily that can metabolize free formaldehyde 
 15 
 
directly [104-106]. However, their Km values for formaldehyde are much greater than the 
one GSNOR shows with HMGSH, suggesting that GSNOR is the more efficient enzyme 
for formaldehyde detoxification [65, 91, 106].  
The functional aspect of GSNOR most relevant to this dissertation is its GSNO 
reductase activity. In 1998, Jensen and co-workers reported that GSNO is a substrate for 
GSNOR and this reduction reaction uses one mol of NADH per mol of GSNO 
metabolized [54]. Product analyses performed by the same research group suggest the 
major stable product is glutathione sulfinamide. However, when an excess of GSH was 
included in the reaction mix in vitro, the formation of GSSG and hydroxylamine 
appeared to be favoured (Figure 1.3.4-1) [54].  A few years later, Liu et al. reported the 
purification of GSNOR from Escherichia coli, Saccharomyces cerevisiae and mouse 
macrophages and demonstrated that GSNOR is highly specific towards GSNO with no 
activity observed towards S-nitrosocysteine and S-nitrosohomocysteine [107]. 
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Figure 1.3.4-1 Proposed reaction scheme for GSNOR catalyzed GSNO degradation 
Image from: Jensen et al. (1998). "S-nitrosoglutathione is a substrate for rat alcohol 
dehydrogenase class III isoenzyme." Biochemical Journal 331 (Pt 2): 659-668. With 
permission. 
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Under physiological redox conditions, the ratio of free NADH / NAD+ is usually 
low [108]. This is considered unfavorable for reductive pathways which require NADH 
and implies that the reductase activity of GSNOR might depend on cofactor availability. 
Various factors could trigger an increase in cellular NADH levels, such as ADH mediated 
ethanol metabolism [109] and the inhibition of NADH dehydrogenase [91]. However, 
whether these events directly contribute to the activation of GSNOR reductase activity 
remain unclear.  A more recent study by Staab et al. suggests that NADH produced by 
GSNOR catalyzed oxidation reactions remain bound to the enzyme and could promote 
GSNO reduction via direct cofactor recycling [110]. In addition, steady state kinetics of 
human GSNOR show that the kcat / Km for GSNO reduction is approximately twice the 
kcat / Km for HMGSH oxidation, and the reduction reaction is essentially irreversible as 
neither glutathione sulfinamide nor GSSG works as substrate or inhibitor for GSNOR 
[111]. With these factors considered, it becomes feasible to drive the reaction in the 
reductive direction despite unfavourable NADH / NAD+ ratios, lending further support 
that GSNOR is a physiologically relevant enzyme for GSNO metabolism.  
Furthermore, GSNOR deficient mice (GSNOR -/-) has been shown to exhibit 
substantial increases in protein S-nitrosation [112]. Since it is generally accepted that in 
the cellular environment, GSNO is in equilibrium with a subset of S-nitrosated proteins 
via reversible transnitrosation (Figure 1.3.4-2), the observation that GSNOR deficient 
mice experience increased levels of S-nitrosation places GSNOR in a crucial role in 
maintaining SNO homeostasis via its GSNO reductase activity.   
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Figure 1.3.4-2 Regulation of SNO homeostasis by GSNOR 
(a) GSNO is in equilibrium with a subset of S-nitrosated proteins. By metabolizing 
GSNO, GSNOR removes NO equivalents from the bioactive NO pool; and indirectly 
promotes protein de-nitrosation. (b) GSNOR knockout mice exhibit increased SNO 
levels with physiological consequences. (c) GSNOR expression and activity are 
associated with human asthma. Image from: Foster et al. (2009). "Protein S-nitrosylation 
in health and disease: a current perspective." Trends in Molecular Medicine 15(9): 391-
404. With permission.  
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 1.3.5 GSNOR’s Involvement in Physiology 
In 2004, Liu et al. generated GSNOR deficient mice (GSNOR -/-) using homologous 
recombination. These animals exhibit increased level of whole cell S-nitrosation, 
increased level of SNO in their red blood cells, and are more susceptible to endotoxic or 
bacterial challenge [112]; suggesting immunity could be affected by SNO and GSNOR 
activity. A number of subsequent studies using this animal model offered additional 
insights into GSNOR’s involvement in physiology. Lima et al. observed an increase in 
myocardial capillary density and cardio-protective characteristics in GSNOR deficient 
animals. These findings are further supported by another study which demonstrated that 
GSNOR -/- mice have preserved cardiac function after myocardial infarction [113].  
In pulmonary physiology, GSNO has been identified as a long-lived and potent 
relaxant of human airways [114]. This endogenous bronchodilator appears to be depleted 
in the airway linings of individuals with asthma, which is a chronic disease characterized 
by airway inflammation and hyper-responsiveness [115]. Interestingly, following an 
allergen challenge, GSNOR null mice have substantially higher levels of SNO in the 
lungs than their wild-type counterparts and are protected from airway hyper-responsivity 
[116]. These observations led researchers to propose a novel therapeutic approach of 
targeted GSNOR inhibition to restore SNO levels and alleviate asthma symptoms. In 
2013, Ferrini et al. reported intranasal administration of the GSNOR inhibitor SPL334 
reduces airway hyper-reactivity, inflammation, and mucus production in a mouse model 
of allergic asthma [117]. A year later, Blonder et al.  published findings showing 
treatment with the GSNOR inhibitor N6022 restores GSNO levels and leads to 
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bronchodilation, as well as reduced inflammation [118]. N6022 is currently undergoing 
clinical evaluation for the treatment of inflammatory lung disease.  
GSNOR and its ability to modulate SNO levels also play a role in cystic fibrosis 
(CF). Development of CF is attributed to mutations in the CFTR gene. The common 
ΔF508 mutation causes protein misfolding, in which case the protein fails to mature and 
is degraded in the endoplasmic reticulum (ER) [119]. A number of studies have 
demonstrated that GSNO can increase CFTR maturation and partially restore the function 
of ΔF508 CFTR by directing it to the plasma membrane [120-122]. Most recently, Zaman 
et al. reported an inverse relationship between GSNOR activity and the expression and 
maturation of CFTR [123], with the implication that pharmacological inhibition of 
GSNOR could potentially benefit patients with CF.   
Since increasing GSNO levels appear to have beneficial consequences in a 
number of cardiovascular and pulmonary conditions, the synthesis and characterization of 
small molecule GSNOR inhibitors have gained attention. [124-127]. However, this 
promising therapeutic approach is complicated by findings which suggest GSNOR 
activity is important for protecting cells from nitrosative stress. For example, the DNA 
repair protein O(6)-alkylguanine-DNA alkyltransferase confers protection against 
alkylation induced mutagenesis in the liver; but GSNOR deficiency results in S-
nitrosation and proteosomal degradation of this key repair protein under inflammatory 
conditions [128-130]. In this context, GSNOR deficient mice are more susceptible to both 
spontaneous and carcinogen-induced hepatocellular carcinoma. Similarly, decreased 
GSNOR activity is associated with human lung cancer via Ras S-nitrosation and 
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activation [131]. These oncogenic potentials should be taken into consideration when 
evaluating therapies involving pharmacological GSNOR inhibition.  
1.4 Neutral Sphingomyelinase II 
 1.4.1 A Brief History of Discovery 
Sphingomyelinase (EC.3.1.4.12) is a family of enzymes which catalyzes the hydrolysis of 
the sphingolipid sphingomyelin (SM) to form bioactive ceramide and phosphocholine. 
Ceramide, along with its downstream metabolites, are important second messenger 
molecules capable of modulating a variety of cellular events, such as cell cycle arrest, 
differentiation, inflammation and apoptosis [132-134].  
The family of sphingomyelinase enzymes can be further divided into three groups 
based on their distinct catalytic pH optimum. Acid sphingomyelinase is responsible for 
the catabolism of SM within lysosomes and deficiency of this enzyme leads to the human 
Niemann-Pick disease [135, 136]. More recently, acid sphingomyelinase has been 
reported to contribute to stress induced ceramide generation and subsequent pro-apoptotic 
signaling pathways [137-142]. On the other hand, alkaline sphingomyelinase is found in 
the intestinal tract, bile and liver; and participates in sphingomyelin digestion [143, 144]. 
Findings by Zhang et al. also suggest the potential involvement of alkaline 
sphingomyelinase in regulating mucosal growth, as well as alkaline phosphatase function 
[145]. 
Neutral magnesium-dependent sphingomyelinase activity was first reported by 
Scheider and Kennedy in 1967 [136]. Since then, several mammalian forms have been 
identified and studied. Neutral sphingomyelinase I was cloned based on remote sequence 
similarity to known bacterial sphingomyelinases in 1998 [146]. A year later, results from 
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overexpression and radiolabeling experiments suggest that this integral membrane protein 
does not hydrolyze sphingomyelin in cultured cells; and instead functions as a lyso-
platelet activating factor (lysoPAF) phospholipase C [147]. However, studies involving 
neutral sphingomyelinase I knockout mouse do not support the proposed 
lysophospholipase C activity [148]. To date, the physiological roles of mammalian 
neutral sphingomyelinase I remain elusive.  
In 2000, Hofmann and colleagues reported the identification of mammalian 
neutral sphingomyelinase II (NSMase II) based on remote similarity to bacterial 
sphingomyelinases using a bioinformatics-based gene discovery approach coupled with 
phylogenetic analysis [149]. This membrane protein consists of 655 amino acid residues 
and has an overall predicted molecular weight of 71 kDa. Biochemical studies of 
NSMase II suggest that it is magnesium-dependent and can be activated by unsaturated 
fatty acids as well as anionic phospholipids, such as phosphatidylserine [149, 150]. 
Unlike neutral sphingomyelinase I, NSMase II exhibits genuine sphingomyelinase 
activity both in vitro and in vivo with overexpression of this enzyme resulting in 
accelerated SM catabolism and an increase in ceramide levels [150]. As a result, NSMase 
II is viewed by many researchers as a prime candidate involved in ceramide generation 
and signaling.  
More recently, neutral sphingomyelinase III was identified using peptide 
sequence from purified bovine sphingomyelinases [151]. A study by Cororan et al. 
suggests this 97 kDa protein may be linked to tumorigenesis and cellular stress response 
[152]. Independent confirmation of its activity and functional roles are yet to be reported.  
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 1.4.2 NSMase II Protein Structure 
Crystal structures of mammalian neutral sphingomyelinases have not yet been reported. 
Therefore, the currently accepted domain structures are based on a combination of amino 
acid sequence analysis, comparison to known bacterial neutral sphingomyelinase 
structures and various biochemical studies. Among the different neutral 
sphingomyelinase enzymes reported, structural homology is relatively low (Figure 1.4.2-
1). 
The proposed domain structure of NSMase II consists of two hydrophobic 
segments near the N-terminus, followed by a 200 residue collagen-like triple helices and 
a catalytic domain near the C-terminus (Figure 1.4.2-1) [149]. Although the two 
hydrophobic segments were initially proposed to be transmembrane domains, subsequent 
analysis of NSMase II membrane topology suggested that these segments do not actually 
span the entire membrane [153]. Two discrete anionic phospholipid (APL) binding 
domains were identified near the N-terminus which allow NSMase II to interact 
specifically with certain APLs including phosphatidylserine and phosphatidic acid [154]. 
The two APL binding domains partially overlap with the hydrophobic segments and 
additional mutagenesis studies reveal that Arg33, Arg45 and Arg48 are essential for 
interaction with APL in the first domain while Arg92 and Arg93 are critical for the 
second domain [154]. NSMase II can also be palmitoylated in two cysteine clusters via 
thioester bonds. This modification appears to be important for protein stability, as well as 
protein localization with palmitoylation deficient mutants showing rapid degradation and 
reduced membrane association [155]. 
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Figure 1.4.2-1 Proposed domain structures of human neutral sphingomyelinases 
 Neutral sphingomyelinase I (accession number O60906), neutral sphingomyelinase II 
(accession number Q9NY59) and neutral sphingomyelinase III (accession number 
NP060421). Image from Wu et al. (2010). "Mammalian Neutral Sphingomyelinases: 
Regulation and Roles in Cell Signaling Responses." Neuromolecular Medicine 12(4): 
320-330. With permission.  
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 1.4.3 Subcellular Localization of NSMase II 
The subcellular localization of NSMase II has been reported mainly in two organelles. 
Hofmann et al. observed localization predominantly at the Golgi in several cell lines 
derived from the brain [149]. In contrast, Marchesini et al. reported localization at the 
plasma membrane in confluence arrested MCF7 cells [156]. This apparent discrepancy in 
localization could be explained by results from subsequent studies which demonstrate 
NSMase II is transported between the plasma membrane and intracellular sites [157]. 
Using A549 epithelial cells, Clarke et al. observed acute translocation of NSMase II to 
the plasma membrane in response to tumor necrosis factor α [158]. In the same year, 
Levy et al. reported preferential trafficking of NSMase II to the plasma membrane under 
conditions of oxidative stress. Conversely, exposure to the antioxidant glutathione leads 
to nuclear localization of NSMase II, where both ceramide generation and apoptosis 
appear to be attenuated [159]. Together, these findings suggest subcellular localization of 
NSMase II affect its function and intracellular trafficking is one of the mechanisms 
regulating its catalytic activity. 
 1.4.4 Physiological Roles of NSMase II 
Since its discovery, NSMase II has been shown to participate in a large number of 
physiological processes. This section will highlight some of the major biological 
functions attributed to NSMase II.  
 
Role of NSMase II in Oxidative Stress 
NSMase II is an important mediator of cellular stress response, mainly through the 
production of ceramide. In human airway epithelial cells (HAEC), exposure to oxidative 
stressors (H2O2 and cigarette smoke) selectively induces the activation of NSMase II; 
 26 
 
with the resultant increase in cellular ceramide leading to HAEC apoptosis and lung 
injury. This apoptotic response to oxidative stress is lost upon siRNA silencing of 
NSMase II [159, 160]. In addition, NSMase II expression level is significantly higher in 
lung tissues obtained from smokers with pulmonary emphysema as compared to normal 
control subjects [161], suggesting an in vivo role of NSMase II in oxidative stress 
induced ceramide generation and lung injury. Interestingly, another study presented 
evidence that NSMase II and ceramide are critical for lung development. Poirier et al. 
studied lung phenotype from fro/fro mice, which express catalytically inactive NSMase II 
due to gene mutation, and noticed these animals exhibit symptoms similar to emphysema 
[162]. This raises the possibility that perhaps basal levels of NSMase II activity are 
required for normal lung development. More research is needed to fully understand this 
enzyme’s biological function in pulmonary physiology.  
In addition to pulmonary physiology, Clement et al. [163] demonstrated that 
certain types of neuronal cells can adapt to chronic oxidative stress by down-regulating 
NSMase activity. These cells exhibit increased intracellular cholesterol levels and are 
resistant to apoptosis. Extracellular treatment of the stress resistant cells with NSMase 
reverses the stress-resistant phenotype; while treating oxidative stress sensitive neuronal 
cells with NSMase inhibitors made the cells more resistant to oxidative stress. 
 
Effect of NSMase II Activity on NOS 
ER stress inhibits NSMase II activity in bovine aortic endothelial cells [164]. When cells 
were treated with the ER stressor palmitate or tunicamycin, reduced NSMase II activity 
leads to less ceramide generation, which attenuates ceramide dependent eNOS activation 
and results in decreases in NO production [165]. Similarly, siRNA mediated knock-down 
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of NSMase II also results in decreased NO generation [164]. This reduced bioavailability 
of NO promotes the dominance of vasoconstriction over vasodilation. As a result, 
decreased NSMase II activity is proposed to be a contributing factor in the induction of 
endothelial dysfunction.  
In C6 rat glioma cells, inhibition of NSMase II activity prevents 
lipopolysaccharide induced iNOS expression, whereas inhibition of acid 
sphingomyelinase activity or ceramide de novo synthesis have no effect; suggesting 
ceramide generated by NSMase II is critical in the regulation of iNOS expression [166]. 
In agreement with this line of evidence, treatment with GW4869, a specific NSMase 
inhibitor, decreases iNOS expression in cultured human retinal pigment epithelial cells. 
This reduces nitrosative stress experienced by these cells and protects them from ER 
stress-induced apoptosis [167]. Overall, it appears that NSMase II catalyzed ceramide 
generation enhances NOS expression and activity. 
 
Role of NSMase II in Inflammation 
Long-term as well as acute stimulation with the pro-inflammatory cytokine tumour 
necrosis factor alpha (TNF-α) activates NSMase II in cultured cells, leading to rapid 
sphingomyelin hydrolysis and ceramide generation [165, 168, 169]. Clark et al. observed 
that exposure to TNF-α results in the translocation of NSMase II to the plasma membrane 
in a time- and dose-dependent manner; and this translocation and activation are 
dependent on p38 MAPK [158] and protein kinase C-delta [170]. In 2012, Barth and 
colleagues reported that TNF-α activates NSMase II in both neurons and non-neuron 
cells, causing ceramide accumulation, ROS formation and apoptosis [171]. 
Mechanistically, residues 309 to 319 of TNF-α receptor (p55) form the neutral 
 28 
 
sphingomyelinase activation domain (NSD) [172]. However, this domain does not 
directly interact with NSMase II. Instead, NSD binds factor-associated with neutral 
sphingomyelinase (FAN) [173, 174], which interacts with receptor for activated C-kinase 
1 (RACK1) [175], which in turn interacts with the polycomb group protein EED [176]. 
EED has been identified as a direct interaction partner for NSMase II [176] and 
physically couples NSMase II to the [RACK1-FAN-TNF receptor] complex allowing the 
transduction of signals initiated by TNF-α. Two other inflammatory cytokines, 
interleukin-1 beta [177, 178] and interferon gamma [179], can also increase NSMase II 
activity. Due to its involvement in these signaling pathways, NSMase II has been 
suggested as a potential drug target for inflammatory diseases [180].  
 
Role of NSMase II in Cancer 
The functional role of NSMase II in cancer initiation and progression has been under 
examination with some conflicting results reported. Nucleotide sequencing in a panel of 
human cancers discovered mutations in the gene encoding NSMase II in a subset of 
human leukemia. These mutations appear to result in defects in NSMase II stability and 
localization [181]. Another study looked at the genome-wide methylation status in 
hepatocellular carcinoma and identified NSMase II as a tumour suppressor, with 
overexpression leading to 50% reduction in proliferation [182]. However, NSMase II has 
also been reported to promote angiogenesis [183] and metastasis in breast cancer by 
regulating exosomal microRNA secretion [184]. Additional research in this area is 
needed before we can determine whether these conflicting findings are due to tissue-
specific functions of NSMase II or some other unknown factors. 
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A number of anti-cancer drugs have been shown to act through NSMase II. Ito et 
al. observed that treatment with the chemotherapeutic drug daunorubicin increases 
NSMase II mRNA and protein levels in MCF7 cells. This up-regulation of NSMase II 
facilitates daunorubicin-induced cell death via ceramide generation [185]. In 
oligodendrocytes, NSMase II over-expression leads to increased ceramide generation and 
enhances apoptosis induced by staurosporine or C(2) ceramide [186]. In addition, 
protopanaxadiol, from the root extract of Panax ginseng, exerts cytotoxic effects against 5 
different cancer cell lines through NSMase II activation and disruption of membrane lipid 
rafts [187].  
 1.4.5 Regulation of NSMase II 
NSMase II is a redox sensitive enzyme and the antioxidant GSH inhibits its upregulation 
[159, 188]. In MCF7 cells, pre-treatment with GSH prevents diamide (thiol depleting 
agent) induced NSMase activation [189]. Similarly, treatment with GSH also protects 
HAEC from oxidative stress induced ceramide generation and apoptosis [159, 160]. It is 
interesting to note that human NSMase II has 23 cysteine residues. Whether these 
residues participate in the redox regulation of NSMase II activity, via modifications such 
as S-nitrosation, remain under investigation.  
All-trans retinoic acid (ATRA) causes G0/G1 growth arrest in many cell types. 
Using MCF7 cells as a model system, Clarke et al. demonstrated that ATRA induced 
growth arrest is mediated by increased NSMase II activity and cellular ceramide levels 
[190]. This increase in NSMase II activity was later found to be mostly due to enhanced 
transcription. Ito et al. [191] uncovered 3 Sp1 sites within the 5’ promoter region of 
NSMase II and presented evidence that ATRA treatment activates PKCδ which 
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phosphorylates Sp1. The phosphorylated Sp1 transcription factor then binds to the 
NSMase II promoter, resulting in increased level of transcription.  
More recently, Filosto and colleagues reported that NSMase II is a 
phosphoprotein with phosphorylation occurring exclusively at serine residues [192]. This 
phosphorylation event was proposed to occur downstream of p38 MAPK and PKC [192]. 
In human airway epithelial cells, exposure to oxidative stress enhances NSMase II 
phosphorylation, which results in increased activity [192, 193]. The phosphatase 
calcineurin has also been reported to bind directly to NSMase II; and when the binding 
site was mutated away, NSMase II would exhibit constitutively elevated phosphorylation 
and activity [192]. Subsequent publication by the same research group identified five 
serine residues which are phosphorylated. Three of these residues (Ser289, Ser292 and 
Ser299) are positioned near the catalytic domain, while the other two (Ser173 and 
Ser208) are adjacent to the calcineurin binding site [193]. Overall, phosphorylation of 
these five serine residues appears to play a critical role in NSMase II activation under 
oxidative stress. In addition, NSMase II protein stability could also be regulated post-
translationally by phosphorylation; with phosphorylation of Ser208 leading to increased 
stability [193]. 
In summary, NSMase II mediated sphingomyelin hydrolysis and ceramide 
generation has emerged as an important component in a number of signaling pathways. 
And as such, aberrant activation or inhibition of NSMase II could potentially contribute 
to the development of pathological conditions. 
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CHAPTER 2 
O-aminobenzoyl-S-nitrosoglutathione is a Novel Fluorogenic Substrate for  
S-nitrosoglutathione Reductase 
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2.1 Introduction 
Class III alcohol dehydrogenase (ADH III) was first isolated and purified from the human 
liver in 1984 by Wagner et al. [63]. Early studies have shown that this enzyme exhibits 
very poor activity towards ethanol, and instead, prefers long chain primary alcohols and 
aldehydes as substrates [63, 64]. A few years later, Koivusalo et al. provided strong 
evidence that ADH III is identical to formaldehyde dehydrogenase which catalyzes the 
NAD+-dependent oxidation of hydroxymethylglutathione (HMGSH) [65]. In 1998, 
Jensen and colleagues discovered that in addition to formaldehyde dehydrogenase 
activity, ADH III can specifically and efficiently reduce S-nitrosoglutathione (GSNO) 
using NADH as the cofactor [54]. As a result of this enzymatic activity, ADH III was 
renamed GSNO reductase (GSNOR) by researchers in the S-nitrosothiol (SNO) signaling 
field.  
SNO is the collective term used to describe molecules containing an NO group 
covalently attached to the sulfur atom of a thiol. GSNO, the substrate for GSNOR, is an 
endogenous SNO derived from glutathione, which is the most abundant cellular thiol. 
GSNO contributes to nitric oxide signaling via transnitrosation (the transfer of its NO 
group to reactive cysteine residues on target proteins). Once S-nitrosated, proteins often 
exhibit altered properties and/or functions. Over the years, there is increasing evidence 
which suggest that dysregulation of S-nitrosation correlates with a broad range of human 
pathologies [34, 194-196]. Since GSNO exists in equilibrium with S-nitrosated proteins, 
many of the biological functions of GSNOR are based on its ability to metabolize GSNO 
and drive protein denitrosation. This implies aberrant expression and/or activity of 
GSNOR could disturb cellular SNO homeostasis and contribute to pathogenesis.   
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Research has demonstrated various roles for GSNOR related to cardiovascular 
and respiratory health and disease. For example, GSNOR deficient mice are protected 
from experimentally induced asthma [116] and show cardio-protection with myocardial 
infarction [197]. GSNOR is linked to asthmatic responsiveness in humans with single 
nucleotide polymorphisms influencing responsiveness to bronchodilators [198, 199]. 
GSNOR also plays roles in vasculogenesis [200], bronchopulmonary dysplasia [201, 
202], lung cancer [131] and cystic fibrosis [123]. The involvement of GSNOR in these 
significant heart- and lung-related pathologies has made it a promising therapeutic target 
for modulating intracellular SNO levels [118, 203, 204]. 
The conventional method for measuring GSNOR activity involves monitoring the 
decrease in absorbance at 340 nm. This decrease in absorbance is due to both NADH and 
GSNO consumption [54]. While this assay is easy to use, its application is limited to 
purified enzyme in vitro. Currently, there are no direct and specific spectroscopic probes 
to monitor GSNOR activity in cultured cell. Such probes would permit studies related to 
the localization and regulation of the enzyme within organelles as well as the direct 
assessment of the effectiveness of GSNOR-specific therapeutics.  
In this chapter, we introduce O-aminobenzoyl-S-nitrosoglutathione (OAbz-
GSNO) as a fluorogenic substrate for GSNOR. The characterization of OAbz-GSNO 
includes in vitro catalytic properties, cell permeability and usefulness in measuring 
GSNOR activity in live, primary murine lung endothelial cells. 
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2.2 Materials 
DNase I (DN25),  glutathione, reduced (G4251), imidazole (I0125), isatoic anhydride 
(I12808), isopropyl β-D-1-thiogalactopyranoside (I6758), lysozyme (L7651), β-
nicotinamide adenine dinucleotide, reduced (N8129), phenylmethylsulfonyl fluoride 
(7626), QAE sephadex (Q25120), sodium nitrite (S2252), sodium phosphate dibasic 
(S7907), sodium phosphate monobasic (S8282) and Triton X-100 (T9284) were 
purchased from Sigma-Aldrich. Glycerol (G3700) and sodium chloride (S2830) were 
purchased from ACP Chemicals. Kanamycin (BP906) and Tris-HCl (BP153) were 
purchased from Fisher Scientific. Dithiothreitol (100597) was purchased from MP 
Biomedicals. The inhibitor N6022 was obtained from MedChem Express, Princeton, NJ. 
2.3 Methods 
2.3.1 S-nitrosoglutathione (GSNO) synthesis 
Reduced glutathione (5 mmol) was dissolved in 8 mL of cold water and 2.5 mL of 2 M 
HCl. Equal amount of sodium nitrite (5 mmol) was added and the reaction mixture was 
stirred at 4°C in the dark for 40 minutes. After 40 minutes, GSNO was precipitated using 
10 mL of cold acetone. Finally, the pink product was washed with cold water (5 X 1 mL) 
and cold acetone (3 X 10 mL) before it was lyophilized for storage at -20°C. 
 2.3.2 O-aminobenzoyl GSNO synthesis  
GSNO (0.15 mmol) was dissolved in 3.0 mL of 0.5 M phosphate buffer (pH 8.5).  To 
this, excess isatoic anhydride (0.9 mmol), which has been previously recrystallized from 
isopropanol, was added and the mixture was stirred at 4°C for 24 hours. After the 
insoluble salts were removed by centrifugation, the clear supernatant was applied onto a 
BioRad econo-column containing 2 mL of packed QAE-Sephadex pre-equilibrated with 
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distilled water. Unreacted isatoic anhydride was removed with 10 mL of wash buffer (0.1 
M phosphate, pH 7.4). OAbz-GSNO, visualized as the red-orange band adhering to the 
top of the column, was then eluted with wash buffer containing 1 M NaCl. 5 µl from each 
of the red-orange fractions corresponding to the product was added to a fluorescence 
cuvette containing 1.0 mL of phosphate buffered saline (PBS). The emission at 415 nm 
was monitored (excitation at 312 nm) before and after the addition of 10 mM 
dithiothreitol (DTT). Fractions which showed maximal fluorescence enhancement in the 
presence of DTT were pooled and aliquoted for subsequent studies. OAbz-GSNO is 
stable for at least 1 year when stored at -80°C, in the absence of repeated freeze-thaw 
cycles. 
2.3.3 NMR characterization 
Pooled OAbz-GSNO was lyophilized and then re-dissolved in minimum volume D2O. 
Spectra were collected on a Bruker 500 MHz Avance III spectrometer using a BBFO 
probe.  Peak assignments were based on a 1H-1H COSY45 spectrum. 1H-13C HMQC and 
HMBC experiments were also performed to help determine 1H-13C correlations. 
2.3.4 ADH5 sub-cloning 
Human ADH5, which encodes full length GSNOR, was purchased from Origene 
(SC119755) and sub-cloned into the bacterial expression vector pET28b using Cold 
Fusion Cloning Kit (MJS BioLynx Inc. SYMC010A1). Cloning strategy involves direct 
ligation of PCR amplified gene of interest to the linearized destination vector.  
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Primers used for PCR were designed according to manufacturer’s guidelines and contain 
bases complimentary to the gene of interest as well as bases complementary to the 
linearized destination vector. The following primers were used for ADH5 sub-cloning: 
Forward 5’– GTGCCGCGCGGCAGCCATATGGCGAACGAGGTTATCAAG –3’ 
Reverse 5’– GTGGTGGTGGTGGTGCTCGAGAATCTTTACAACAGTTCGAATG –3’ 
Prior to the ligation reaction, destination vector pET28b was linearized by digestion with 
restriction enzymes NdeI and XhoI; and both PCR amplified ADH5 and linearized 
pET28b were gel purified. Ligation was performed according to manufacturer’s protocol 
and the ligated plasmid DNA was transformed directly into chemically competent DH5 
E.coli. Colonies were screened using diagnostic restriction enzyme digest and later by 
partial sequencing (Robart’s Research Institute, London Regional Genomics Center, 
London, Ontario, Canada). The final recombinant GSNOR contains two 6X-histidine 
tags, one at each terminus. 
2.3.5 GSNOR expression and purification 
pET28b_ADH5 was transformed into BL21(DE3) E.coli. This plasmid encodes full 
length human GSNOR with terminal 6X-histidine tags to facilitate purification. A single 
colony from the transformation plate was inoculated into 25 mL of 2X YT medium 
containing 50 µg/mL kanamycin and the culture was grown overnight at 37°C with 
shaking. This overnight starter culture was then used to inoculate 1L of 2X YT medium 
containing 50 µg/mL kanamycin and the culture was again grown at 37°C until optical 
density reached approximately 0.6. At this point, GSNOR expression was induced by the 
addition of IPTG to a final concentration of 0.4 mM. The induced culture was grown for 
an additional 24 hours at room temperature with shaking before cells were harvested by 
 37 
 
centrifugation (4000 g, 30 minutes, 4°C). Following centrifugation, the supernatant was 
discarded and the bacterial cell pellet was resuspended in lysis buffer (50 mM Tris-HCl 
pH 8, 150 mM NaCl, 15 mM imidazole, 1 mM DTT, 1 mM PMSF, 0.5% Triton X-100, 
50 µg/mL DNase I and 100 µg/mL lysozyme). The crude lysate was incubated on ice for 
30 minutes and further lysed by pulse sonication (20 seconds on, 20 seconds off, 30 
cycles). Another round of centrifugation (11300 g, 30 minutes, 4°C) was performed to 
clarify the lysate and the clarified supernatant was applied to nickel affinity column 
(Sigma P6611)  pre-equilibrated with lysis buffer. Affinity purification was performed 
strictly following manufacturer’s protocol published by Sigma Aldrich with some 
modifications in buffer composition. The wash buffer contains 50 mM Tris-HCl pH 8, 
150 mM NaCl and 50 mM imidazole while the elution buffer contains 50 mM Tris-HCl 
pH 8, 150 mM NaCl and 300 mM imidazole. Finally, the eluted protein was buffer 
exchanged into storage solution (58 mM Na2HPO4, 17 mM NaH2PO4, 68 mM NaCl, 15% 
glycerol) using Amicon centrifugal filter (Millipore UFC903008). When stored at -80°C, 
purified GSNOR is stable and can retain its activity for at least 6 months. 
2.3.6 GSNOR enzyme assay using GSNO as the substrate 
NADH stock solution (20 mM) was prepared with MilliQ water. GSNO stock solutions 
(10 mM and 1 mM) were prepared fresh daily using PBS. Total reaction volume was kept 
at 500 µL using PBS as the reaction buffer. Each reaction contained 80 µM NADH and 
indicated concentration of GSNO. Reaction was initiated by the addition of purified 
GSNOR (1 µg) and the rate of NADH consumption was quantified by measuring the rate 
of absorbance decrease at 340 nm. Each reaction was monitored for 120 seconds using 
Agilent 8453 UV/Vis spectrophotometer at 25°C. 
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2.3.7 GSNOR enzyme assay using OAbz-GSNO as the substrate 
OAbz-GSNO concentration was determined by measuring its absorbance at 320 nm (ε ≈ 
2800 M-1 cm-1). Necessary dilutions were made using PBS. NADH stock solution (20 
mM) was prepared using MilliQ water. Total reaction volume was kept at 500 µL using 
PBS as the reaction buffer. Each reaction contained 80 µM NADH and indicated 
concentration of OAbz-GSNO ranging from 0 to approximately 720 µM. Reaction was 
initiated by the addition of purified GSNOR (1 µg) and initial reaction rates were 
determined by monitoring fluorescence increase (excitation 312 nm; emission 415 nm) 
for 2 minutes using Cary Eclipse fluorescence spectrophotometer.  
2.3.8 GSNOR inhibition studies  
Stock solutions (50 mM) of the GSNOR-specific inhibitors N6022 and C3 were prepared 
using DMSO. Similar to the assay mentioned in Section 2.3.7, total reaction volume was 
500 µL and each reaction contained 40 µM NADH, 1 µg GSNOR and various amounts of 
inhibitor. The range of inhibitor concentration studied was 0 to 1000 nM for N6022 and 0 
to 50 µM for C3. Reaction was initiated by adding 110 µM OAbz-GSNO and changes in 
fluorescence were monitored for 2 minutes. 
2.3.9 Isolation and culture of murine lung endothelial cells 
C57BL/6 mice (4 – 6 weeks) were anesthetized by CO2 inhalation. After the animal’s 
skin was cleaned with 70% ethanol, lung tissues were removed and placed in a 50 mL 
conical tube containing DMEM and shipped to Cell Biologics (Chicago, Il) for isolation 
of primary lung endothelial cells. Tissue slices were prepared, washed and suspended in 
Hanks balanced saline solution (HBSS). After excess HBSS was removed, tissue slices 
were minced and transferred to a sterile tube. Minced tissues were digested and the 
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released cells were harvested by centrifugation. Cells collected were incubated with 
primary antibody against platelet/endothelial cell adhesion molecule 1 (PECAM-1), 
followed by the addition of magnetic beads pre-coated with secondary antibody. Finally, 
cells released from the magnetic beads were washed and cultured on gelatin coated 
culture dishes. These primary lung endothelial cells were characterized by their typical 
cobblestone morphology, PECAM-1/CD31 and VE-cadherin expression as well as Dil-
Ac LDL uptake. Isolated endothelial cells were grown in complete mouse endothelial cell 
medium (Cell Biologics) supplemented with attachment factor (Cell Biologics). Cells 
between passage 3 and 7 were used for all subsequent studies. 
2.3.10 Live cell imaging 
Primary pulmonary endothelial cells from C57BL/6 mice were grown on glass coverslips, 
washed 2 times with Dulbecco’s phosphate buffered saline (DPBS with Ca2+ and Mg2+) 
and loaded with 1.85 mM OAbz-GSNO for 10 mins at 37°C in the cell culture incubator. 
Unloaded cells were used as negative controls. For studies involving GSNOR inhibitors, 
cells were first treated with either 25 µM C3 or 25 µM N6022 for 1 hour at 37°C and 
then loaded with OAbz-GSNO. Their respective paired controls (+ inhibitor / - OAbz-
GSNO) were included for comparison. Following OAbz-GSNO loading, cells were 
washed 4 times with DPBS before imaging. When cells were ready to be imaged, the 
coverslip with cells was placed in a stainless steel chamber and mounted on Zeiss 780 
confocal microscope stage. Cells were imaged in DPBS with 40X NA1.1 water objective. 
During the course of imaging, cells were maintained at 37°C using stage temperature 
control and under humidified gas flow. The compound OAbz-GSNO was excited using 
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2p 740 nm at 3% and emission was collected from 411-482 nm range with 800v PMT at 
5 second intervals over 5 minutes using Time Series. 
2.4 Results and Discussion 
 2.4.1. OAbz-GSNO synthesis 
OAbz-GSNO synthesis consists of two steps. In the first step, reduced glutathione is 
reacted with acidified nitrite to form GSNO (Figure 2.4.1-1 A). This well-characterized 
reaction is fast with high yields. Product can be precipitated using acetone and stored as 
solid powder. When stored at -20°C, GSNO is stable for at least 6 month. In the second 
step, OAbz-GSNO is formed by the nucleophilic attack of the α-amino group of 
glutathione on the anhydride carbonyl of isatoic anhydride (Figure 2.4.1-1 B). The final 
product OAbz-GSNO can either be lyophilized or stored directly as a solution in -80°C.  
 
  
 41 
 
 
 
 
 
Figure 2.4.1-1 OAbz-GSNO synthesis is a two-step process 
(A) Synthesis of GSNO using GSH and acidified sodium nitrite. (B) GSNO reacts with 
isatoic anhydride to produce OAbz-GSNO. 
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2.4.2 NMR characterization 
NMR spectra were used to confirm the success of OAbz-GSNO synthesis. By 
comparison to the starting material GSNO, attachment of the O-aminobenzoyl group 
resulted in significant chemical shift for the glutamate α proton (3.74 ppm to 4.22 ppm) 
as well as the appearance of aromatic proton signals (Figures 2.4.2-1 and 2.4.2-2, Table 
2.4.2). These observations are in agreement with predicted chemical shift changes, and 
provide strong evidence for the successful synthesis of OAbz-GSNO.  
In addition to OAbz-GSNO, NMR also identified a minor chemical species in 
which the nitroso-group is absent (i.e. OAbz-GSH, peaks denoted by *). Formation of 
OAbz-GSH is most likely due to small amounts of GSH present in the starting material 
rather than NO loss post-synthesis as peaks corresponding to GSH were detected in the 
starting material.  
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Figure 2.4.2-1 1H NMR of GSNO 
Lyophilized GSNO was dissolved in minimum volume D2O. Spectrum was collected on 
a Bruker 500 MHz Avance III spectrometer using a BBFO probe. 
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Figure 2.4.2-2 1H NMR of OAbz-GSNO 
Lyophilized OAbz-GSNO was dissolved in minimum volume D2O. Spectrum was 
collected on a Bruker 500 MHz Avance III spectrometer using a BBFO probe.  
  
 45 
 
Table 2.4.2 1H NMR chemical shifts of GSNO and OAbz-GSNO 
 
 
GSNO 
(500 MHz, D2O, δ) 
2.04 (m, 2H, Glu Hβ) 
2.33 (t, 2H, Glu Hγ) 
3.74 (t, 1H, Glu Hα) 
3.84 (s, 1H, Gly Hα) 
3.87 (b, 1H, Cys Hβ) 
4.00 (b, 1H, Cys Hβ) 
4.54 (t, 1H, Cys Hα) 
 
 
 
OAbz-GSNO 
(500 MHz, D2O, δ) 
1.94 (m, 1H, Glu Hβ) 
2.12 (m, 1H, Glu Hβ) 
2.28 (t, 2H, Glu Hγ) 
3.55 (s, 2H, Gly Hα) 
3.80 (b, 1H, Cys Hβ) 
3.96 (b, 1H, Cys Hβ) 
4.22 (q, 1H, Glu Hα) 
4.52 (t, 1H, Cys Hα) 
6.75-7.90 (aromatic H) 
Abbreviations: δ, chemical shift in parts per million (ppm) downfield from the standard 
Multiplicities: s, singlet; t, triplet; q, quartet; m, multiplet; b, broadened 
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 2.4.3 Fluorescence properties of OAbz-GSNO 
Based on previous studies with fluorescently tagged S-nitrosothiols [205-207], the –SNO 
group can quench a fluorophore if two conditions are met:  
1) The fluorophore excitation spectrum overlaps the –SNO absorbance spectrum. 
2) The overall structure of the molecule permits the fluorophore and the –SNO moiety to 
be in close physical proximity. 
The fluorophore O-aminobenzoyl fulfills both conditions. First, the excitation spectrum 
of O-aminobenzoyl exhibits λmax at around 312 nm. This overlaps the –SNO absorbance 
spectrum with its λmax at around 335 nm. Second, since GSNO is a small molecule, its 
physical structure allows O-aminobenzoyl and –SNO to come into close proximity, 
resulting in fluorescence quenching. Chemical changes to the –SNO functionality, such 
as loss of NO via denitrosation or reduction of –SNO to –SNHOH by GSNOR, would 
lead to a loss in spectra overlap (Figure 2.4.3-1). This in turn results in enhanced 
fluorescence that could be detected.   
Consistent with this concept, OAbz-GSNO is only weakly fluorescent upon 
synthesis. Denitrosation mediated by the addition of strong reducing agent DTT increases 
OAbz-GSNO fluorescence by approximately 14 fold (Figures 2.4.3-2). This increase in 
fluorescence is the direct consequence of NO loss, which removes the quenching effect.  
In addition to OAbz-GSNO, Eosin-GSNO and dansyl-GSNO were also 
synthesized and screened for their applicability. Both Eosin-GSNO and dansyl-GSNO 
exhibit insufficient fluorescence quenching and are determined to be poor substrates for 
GSNOR.    
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Figure 2.4.3-1 Spectral difference between GSNO and NH2OH 
GSNO exhibits maximum absorbance at 335 nm. This overlaps with the O-aminobenzoyl 
excitation spectrum. Hydroxylamine (NH2OH), on the other hand, does not absorb in this 
wavelength range.   
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Figure 2.4.3-2 DTT mediated OAbz-GSNO denitrosation results in significant 
fluorescence enhancement  
(A) Addition of DTT to the final concentration of 10 mM increases OAbz-GSNO 
fluorescence (excitation 312 nm, emission 415 nm) by approximately 14 fold. (B) 
Fluorescence emission spectra of 75 µM OAbz-GSNO before (dash line) and after (solid 
line) the addition of 10 mM DTT. Excitation wavelength is set to 312 nm. 
0
100
200
300
400
500
600
0 1 2 3 4 5
R
F
U
Time (minute)
0
100
200
300
400
500
350 400 450 500 550
R
F
U
Wavelength (nm)
A 
+
 D
T
T
 
B 
 49 
 
 2.4.4 OAbz-GSNO is a fluorogenic substrate for GSNOR 
To assess whether OAbz-GSNO works as a fluorogenic substrate for GSNOR in vitro, 
full length human ADH5 (NCBI reference sequence NM_000671.3), which encodes 
GSNOR, was cloned into an E. coli expression vector for recombinant protein 
production. Cloning success was verified by diagnostic restriction digest and partial DNA 
sequencing.  
The recombinant GSNOR protein carries two poly-histidine tags, one at each 
terminus, to facilitate Nickel affinity purification. Purified GSNOR exhibits monomeric 
mass of approximately 40 kDa (Appendix C). Conventional NADH consumption assay 
was used to determine whether the purified GSNOR is active in vitro. As shown in 
Figure 2.4.4-1, in the absence of substrate, absorbance at 340 nm was relatively constant. 
When substrate (50 µM GSNO) was included in the reaction mixture, GSNOR catalyzed 
GSNO reduction led to a rapid decrease in absorbance as both GSNO and the cofactor 
NADH were being consumed.  
Next, a series of experiments were performed using OAbz-GSNO as the substrate. 
Results show that GSNOR mediated reduction of OAbz-GSNO is capable of removing 
the quenching effect and causes OAbz-GSNO fluorescence to increase in a time 
dependent manner (Figure 2.4.4-2). Specifically, OAbz-GSNO is stable in the absence of 
GSNOR for up to 45 minutes, as evidenced by no fluorescence increase. Upon the 
addition of GSNOR, fluorescence begins to increase over time. After 45 minutes, 
approximately 10 fold increase in fluorescence was observed. When compared to the 
chemical reduction of OAbz-GSNO by DTT, the full 14 fold increase in fluorescence was 
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not observed in this enzymatic reaction since not all of the OAbz-GSNO was converted 
to product within 45 minutes.  
The kinetic parameters of GSNOR using OAbz-GSNO as the substrate were also 
assessed. Time dependent changes in fluorescence were monitored as a function of 
OAbz-GSNO concentration in the presence of catalytic amounts of purified GSNOR. The 
initial rates of fluorescence change per unit time were hyperbolic with an apparent Km of 
320 µM (Figure 2.4.4-3). Vmax was estimated to be 19.1 fluorescent units per minute, 
which equals approximately 1.65 nmol –SNO reduced per minute based on the 
calibration curve (Figure 2.4.4-4). Both Km and Vmax were calculated using the Excel 
analysis tool Solver. The observed Km value of 320 µM for OAbz-GSNO is much larger 
than the previously reported Km value of 28 µM for GSNO [54, 111]. This is likely due to 
the bulk of the O-aminobenzoyl group not being well accommodated by the GSNOR 
active site.  
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Figure 2.4.4-1 Purified recombinant GSNOR is active 
Absorbance at 340 nm was monitored as a function of time. Each reaction contains 1 µg 
GSNOR, 80 µM NADH, and GSNO at indicated concentrations. PBS was used as the 
reaction buffer.   
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Figure 2.4.4-2 GSNOR mediated reduction of OAbz-GSNO leads to increased 
fluorescence 
Comparison of OAbz-GSNO (10 µM) fluorescence emission spectra in the presence of 
NADH (10 µM) without GSNOR at t= 0, 5 and 45 minutes; as well as in the presence of 
GSNOR (6 µg) and NADH (10 µM) at t= 0, 5, 15, 30 and 45 minutes. PBS was used as 
the reaction buffer. Excitation wavelength was set to 312 nm.  
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Figure 2.4.4-3 Kinetic characterization of OAbz-GSNO 
Initial rates of OAbz-GSNO fluorescence increase (excitation at 312 nm, emission at 415 
nm) were determined as a function of OAbz-GSNO concentration in the presence of 
GSNOR (1 µg) and NADH (80 µM). Error bars represent standard deviation (n=5). 
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Figure 2.4.4-4 OAbz-GSNO calibration curve  
Known amounts of OAbz-GSNO were fully reduced using DTT. Quantitative changes in 
fluorescence (excitation at 312 nm, emission at 415 nm) were recorded. Error bars 
represent standard deviation (n=5).  
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 2.4.5 In vitro GSNOR inhibition studies 
To further confirm that the observed fluorescence increase was specifically due to 
GSNOR mediated –SNO reduction, GSNOR inhibitors N6022 and C3 were used (Figure 
2.4.5-1). Both inhibitors were able to prevent OAbz-GSNO fluorescence increase in 
vitro. This demonstrates substrate fluorescence is responsive to GSNOR activity.   
Based on this set of experiments, the IC50 of N6022 was estimated to be 21.1 nM 
± 3.1 nM (Figure 2.4.5-2 A); while the estimated IC50 of C3 was 1.9 µM ± 0.2 µM 
(Figure 2.4.5-2 B). The IC50 value obtained for C3 was very close to the previously 
reported value of 1.1 µM [124]. On the other hand, the estimated IC50 of 21.1 nM for 
N6022 was slightly larger than the reported value of 8 nM [126]. This lower affinity 
observed for N6022 with OAbz-GSNO is likely related to the fact that N6022, as an 
uncompetitive inhibitor, binds to the enzyme-substrate complex. The higher IC50 
observed suggests that the bulkiness of the O-aminobenzoyl moiety might decrease 
interactions between active site bound substrate and N6022. Conversely, noncompetitive 
inhibitors (such as C3) bind to a site peripheral to the active site. In this case, the binding 
of C3 was not affected, as evidenced by the close to reported IC50 obtained using OAbz-
GSNO as the substrate. 
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Figure 2.4.5-1 Structures of GSNOR-specific inhibitors   
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Figure 2.4.5-2 GSNOR-specific inhibitors N6022 and C3 inhibit GSNOR-mediated 
OAbz-GSNO reduction in vitro 
(A) Initial rates of OAbz-GSNO fluorescence change were monitored at 415 nm 
(excitation at 312 nm). Each reaction contained 110 µM OAbz-GSNO, 1 µg GSNOR, 80 
µM NADH and varying amounts of N6022. (B) Similarly, initial rates of OAbz-GSNO 
fluorescence change were monitored at 415 nm with varying amounts of C3 included in 
each reaction. Error bars represent standard deviation (n=3). 
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 2.4.6 OAbz-GSNO is cell permeable 
Confocal microscopy was used to assess membrane permeability of OAbz-GSNO. GSNO 
alone is largely hydrophilic and does not readily cross cell membranes. However, the 
addition of aromatic groups to make charged hydrophilic compounds membrane 
permeable is a well-established technique in pharmacology [208]. By exposing primary 
endothelial cells to OAbz-GSNO and monitoring fluorescence at 410 nm, strong 
fluorescence was observed in the perinuclear/Golgi region of these cells (Figure 2.4.6-1 
B), clearly demonstrating that OAbz-GSNO is cell membrane permeable. Furthermore, 
GSNOR is localized to the same subcellular region as visualized by immunofluorescence 
(Figure 2.4.6-1 A). Since both enzyme and substrate are in the same subcellular 
compartment, this will likely facilitate GSNOR mediated reduction of OAbz-GSNO.  
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Figure 2.4.6-1 GSNOR and OAbz-GSNO exhibit similar subcellular localization 
patterns in primary murine lung endothelial cells 
(A) Primary mouse lung endothelial cells were grown on coverslips, fixed with 3.7% 
formaldehyde and permeabilized with digitonin. GSNOR expression was visualized using 
anti-GSNOR primary antibodies and Alexa Fluor 488 secondary antibodies. (B) Primary 
mouse lung endothelial cells were grown on glass coverslips and loaded with 1.85 mM 
OAbz-GSNO for 10 minutes at 37°C. Fluorescence from live cells was visualized using 
Zeiss 780 confocal microscope. Imaging studies were performed by Dr. Lisa Palmer and 
colleagues at the University of Virginia.  
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 2.4.7 Live-cell imaging studies  
Similar to the in vitro experiments, live-cell imaging studies demonstrate that the 
fluorescence of OAbz-GSNO loaded cells increases over time, indicating that the –SNO 
functionality of OAbz-GSNO is being altered (Figure 2.4.7-1). To determine if the 
observed fluorescence change is due to endogenous cellular GSNOR activity, cells were 
treated with GSNOR-specific inhibitors (N6022 or C3) prior to OAbz-GSNO loading. 
Upon GSNOR inhibition, the rate of fluorescence increase in OAbz-GSNO loaded cells 
is reduced to levels comparable to no treatment control cells (Figure 2.4.7-1). This offers 
strong evidence that the observed increase in live cell fluorescence is reporting on 
endogenous GSNOR activity.   
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Figure 2.4.7-1 N6022 and C3 inhibit GSNOR-mediated fluorescence increase in cells 
loaded with OAbz-GSNO 
(A) Average perinuclear fluorescence (PF), in all cells in the field of view, was obtained 
from time-image stack, digitized with ImageJ and the Time Series Analyzer V3 plugin. 
Blue circles – cells were loaded with 1.85 mM OAbz-GSNO; red circles – cells were 
first treated with 25 µM N6022 for 1 hour, and then loaded with OAbz-GSNO; purple 
circles – cells were first treated with 25 µM C3 for 1 hour, and then loaded with OAbz-
GSNO; green circles – no treatment control cells. (B) Images collected from stack at t=0 
and t=150 second (t=120 second for C3) with PF values indicated. Imaging studies were 
performed by Dr. Lisa Palmer and colleagues at the University of Virginia. 
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2.5 Conclusion 
In this chapter, we report the synthesis and characterization of OAbz-GSNO as a 
fluorogenic substrate for the enzyme GSNOR (Figure 2.5). The fluorescence of OAbz-
GSNO can be turned on by either chemical or enzyme-mediated reduction of its –SNO 
moiety in vitro. Furthermore, this substrate can be taken up by primary cells in culture 
and accumulates in the same subcellular compartment as GSNOR. Results from live-cell 
imaging studies demonstrate endogenous GSNOR activity results in detectable increases 
in OAbz-GSNO fluorescence; and this increase in fluorescence is abolished by GSNOR 
inhibitor treatment. To the best of our knowledge, OAbz-GSNO is the first compound 
which is capable of reporting on endogenous GSNOR activity in live cells. 
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Figure 2.5 OAbz-GSNO is a fluorogenic substrate for GSNOR 
OAbz-GSNO experiences fluorescence quenching and exhibits minimal fluorescence. 
Chemical or enzymatic reduction of its –SNO functional group leads to significant 
fluorescence increase. OAbz-GSNO is membrane permeable and can be used to assess 
endogenous GSNOR activity in live cells.  
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CHAPTER 3  
Investigations into the Regulation of S-nitrosoglutathione Reductase Activity at the  
Post-Translational Level 
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3.1 Introduction 
S-nitrosoglutathione reductase (GSNOR) is an evolutionarily conserved, multi-functional 
enzyme. It can effectively catalyze both the oxidation of hydroxymethylglutathione 
(HMGSH) [65], and the reduction of S-nitrosoglutathione (GSNO) [54, 107]. As a result 
of these enzymatic activities, functional studies of GSNOR have largely focused on its 
involvement in cellular formaldehyde detoxification; as well as S-nitrosothiol (SNO) 
homeostasis and nitric oxide (NO) signaling. Despite its universal pattern of expression 
[85] and demonstrated involvement in human physiology, not much is known regarding 
the regulation of its activity, especially at the post-translational level.  
Structurally, GSNOR is a metalloenzyme with two coordinated zinc ions (Zn2+) 
per subunit. Primary amino acid sequence analysis reveals a CxxC zinc finger motif as a 
part of the structural zinc binding site. In addition to metal binding, the CxxC motif, in 
which two cysteine residues are separated by two other residues, is a well characterized 
redox motif [209]. Proteins such as thioredoxins and protein disulfide isomerase (PDI) 
use this motif for the formation, reduction and isomerization of protein disulfide bonds 
[210-212]. It is widely accepted that the two residues in between the cysteines exert 
substantial influences on the redox potential of this motif. More recently, Kimura et al. 
studied the conserved lysine residue immediately following the CxxC motif in PDI and 
demonstrated that this lysine residue (CxxCK) significantly increases PDI isomerase 
activity [213]. Acetylation of this lysine was subsequently suggested as a possible post-
translational modification involved in the regulation of PDI activity [214]. Interestingly, 
the zinc binding CxxC motif within GSNOR is also flanked by a highly conserved lysine 
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residue (CxxCK101). Whether K101 contributes to the regulation of GSNOR activity is 
currently unknown.  
This chapter focuses on in vitro kinetic evaluation of wild-type and mutant 
GSNOR to assess the role of K101 and to investigate potential post-translational 
regulations of GSNOR activity.  
3.2 Materials 
Acetic anhydride (320102), DNase I (DN25),  glutathione, reduced (G4251), imidazole 
(I0125), isopropyl β-D-1-thiogalactopyranoside (I6758), lysozyme (L7651), β-
nicotinamide adenine dinucleotide, reduced (N8129), phenylmethylsulfonyl fluoride 
(7626), sodium nitrite (S2252), sodium phosphate dibasic (S7907), sodium phosphate 
monobasic (S8282) and Triton X-100 (T9284) were purchased from Sigma-Aldrich. 
Glycerol (G3700) and sodium chloride (S2830) were purchased from ACP Chemicals. 
Kanamycin (BP906) and Tris-HCl (BP153) were purchased from Fisher Scientific. 
Dithiothreitol (100597) was purchased from MP Biomedicals. 
3.3 Methods 
 3.3.1 Computational modeling and simulations 
The Molecular Operating Environment (MOE, 2013.08; Chemical Computing Group Inc. 
Montréal, QC, Canada) software package was used to perform all docking and molecular 
dynamics (MD) simulations. 
GSNOR crystal structure (PDB ID: 3QJ5) was used as the template for the 
investigation. Initial crystallographic data was prepared using MOE software by 
removing the waters and resolving the system up to 6 Å away from any residue. The 
structure was then allowed to relax using the AMBER12: EHT force field to remove any 
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strain from the preparation of the protein structure. Finally, in order to allow for thermal 
relaxation and multiple conformers generation, the minimized structure was used as 
starting point for a 3 ns MD simulation. An estimated average structure found in the 
production run was selected for additional analysis.  
For docking experiments, the substrate GSNO was docked into its known active 
site using the induced fit formulism. Virtual screening was then employed to identify 
other potential GSNO binding sites. To evaluate the top poses, London dG scoring 
function was used with the AMBER12: EHT force field refinement keeping the top 10 
scores. 
 3.3.2 GSNO synthesis 
Reduced glutathione (5 mmol) was dissolved in 8 mL of cold water and 2.5 mL of 2 M 
HCl. To this solution, 5 mmol of sodium nitrite was added and the reaction was stirred at 
4°C in the dark for 40 minutes. After 40 minutes, GSNO was precipitated using 10 mL of 
cold acetone. The precipitate was collected via filtration, washed with cold water (5 X 1 
mL), cold acetone (3 X 10 mL), and lyophilized for storage at -20°C. 
 3.3.3 Site-directed mutagenesis  
The residue Lys101 of human GSNOR was mutated to either alanine (K101A) or 
glutamine (K101Q) using Q5 Site-Directed Mutagenesis Kit (New England BioLabs 
E0554). PCR primers were designed to be end-to-end with the forward primer carrying 
the mutagenic sequence resulting in single amino acid substitution. The following 
primers were used: 
K101A Forward 5’ – TGG AGA ATG CGC ATT TTG TCT AAA TCC – 3’ 
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K101A Reverse 5’ – CAC TGT GGG ATG TAA AGT G – 3’ 
K101Q Forward 5’ – GGA GAA TGC CAA TTT TGT CTA AAT CCT – 3’ 
K101Q Reverse 5’ – ACA CTG TGG GAT GTA AAG TG – 3’ 
PCR reaction was set up according to manufacturer’s recommendations and thermal 
cycling conditions were optimized for each primer set. The resultant PCR product was 
treated with Kinase, Ligase, Dpn1 enzyme mix according to manufacturer’s protocol and 
used to transform chemically competent DH5 E.coli (New England BioLabs C2987). 
Individual colonies from the transformation plates were selected and each colony was 
inoculated into 3 mL of LB medium (with 50 µg/mL kanamycin) for overnight growth at 
37°C. Plasmid DNA was then isolated from these cultures using a standard bacterial 
miniprep procedure (Qiagen). Isolated plasmid DNA was resuspended in TE buffer and 
sequenced at Robart’s Research Institute (London Regional Genomics Center, London, 
Ontario, Canada) using T7 sequencing primer. Successful mutants were selected for 
subsequent transformation and protein expression.  
 3.3.4 Protein expression and purification 
Expression plasmids pET28b_GSNOR, pET28b_GSNOR_K101A and 
pET28b_GSNOR_K101Q were individually transformed into chemically competent 
BL21(DE3) E.coli (New England BioLabs C2527). Recombinant proteins contain 
terminal 6X-histidine tags to facilitate purification. A single colony from the 
transformation plate was inoculated into 25 mL of 2X YT medium containing 50 µg/mL 
kanamycin and the culture was grown overnight at 37°C. This overnight starter culture 
was then used to inoculate 500 mL of 2X YT medium containing 50 µg/mL kanamycin 
and the culture was grown at 37°C until optical density reached approximately 0.6. At 
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this point, protein expression was induced by the addition of IPTG to a final 
concentration of 0.4 mM. The induced culture was grown for an additional 24 hours at 
room temperature before cells were harvested by centrifugation (4000 g, 30 minutes, 
4°C). Following centrifugation, supernatant was discarded and the bacterial cell pellet 
was resuspended in 15 mL of lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 15 mM 
imidazole, 1 mM DTT, 1 mM PMSF, 0.5% Triton X-100, 50 µg/mL DNase I and 100 
µg/mL lysozyme). The crude lysate was incubated on ice for 30 minutes and further lysed 
by pulse sonication (20 seconds on, 20 seconds off, 30 cycles). Another round of 
centrifugation (11300 g, 30 minutes, 4°C) was performed and the clarified supernatant 
was applied to nickel affinity column (Sigma P6611)  pre-equilibrated with lysis buffer. 
Affinity purification was performed strictly following manufacturer’s protocol published 
by Sigma Aldrich with some modifications in buffer composition. The wash buffer 
contained 50 mM Tris-HCl pH 8, 150 mM NaCl and 50 mM imidazole while the elution 
buffer contained 50 mM Tris-HCl pH 8, 150 mM NaCl and 300 mM imidazole. Finally, 
eluted protein was buffer exchanged into storage solution (58 mM Na2HPO4, 17 mM 
NaH2PO4, 68 mM NaCl, 15% glycerol) using Amicon centrifugal filter (Millipore 
UFC903008). When stored at -80°C, purified proteins are stable and can retain their 
activity for at least 6 months in the absence of repeated freeze-thaw cycles. 
 3.3.5 Kinetic assays  
NADH stock solution (20 mM) was prepared with MilliQ water. GSNO stock solutions 
(10 mM and 1 mM) were prepared fresh daily using PBS. Total reaction volume was kept 
at 500 µL using PBS as the reaction buffer. The various GSNO and NADH 
concentrations used in the assays are noted in the Figure legends.  
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For the set of GSNO pre-treatment experiments, wild-type and mutant GSNOR 
were incubated with 0.5 mM GSNO in the dark for 30 minutes at room temperature. 
Following incubation, unreacted GSNO was removed using Zeba desalting columns 
(Fisher Scientific 89882). For chemical acetylation experiments, acetic anhydride (1 M) 
stock solution was prepared using methanol due to its reactivity. Wild-type and mutant 
GSNOR were then treated with 20 mM acetic anhydride for 1 hour at room temperature 
before enzyme activities were assayed. Each individual reaction was initiated by the 
addition of enzyme (2 µg) and decreases in absorbance at 340 nm were monitored for 90 
seconds using Agilent 8453 UV/Vis spectrophotometer. 
 3.3.6 Immunoblotting  
Wild-type and mutant GSNOR were treated with 20 mM acetic anhydride for 1 hour at 
room temperature. Enzymes mock-treated with equal volume of methanol or GSNOR 
storage buffer were used as controls. Following treatment, samples were resolved using 
10% SDS-PAGE gels and transferred onto polyvinylidene difluoride (PVDF) 
membranes. Blocking was carried out for 1 hour at room temperature using 5% skim 
milk. Membranes were then incubated with primary antibodies against acetyl-lysine 
(1:1000; Abcam ab61384) or 6X histidine (1:1000; Signal Chem H99-61M) overnight at 
4°C, washed 3 times with TBST, and incubated with HRP-conjugated secondary 
antibody (1:5000; Abcam ab97023) for 1 hour. Finally, the membranes were washed 3 
times again and visualized using enhanced chemiluminescence reagents (Thermo 
Scientific 34095).  
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3.4 Results and Discussion 
 3.4.1 Computational modeling and simulations  
GSNOR is a dimeric protein. Each subunit contains a CGEC motif (Figure 3.4.1-1 A). 
This motif participates in the coordination of GSNOR structural zinc. We are interested 
in the highly conserved lysine residue adjacent to the CGEC motif (CGECK101) and 
whether acetylation of K101 affects GSNOR function.  
 Computational modeling and molecular dynamic simulations were performed to 
predict changes due to K101 acetylation. Results show modification of K101 leads to 
significant alterations in protein structure within the structural zinc binding site (Figure 
3.4.4-1 B). This is associated with changes in the distance between GSNOR structural 
zinc and each of the four Cys residues (C97, C100, C103 and C111) involved in its 
coordination (Table 3.4.1-1). Cysteine thiol pKa values were also predicted based on 
average protein structures. Interestingly, the predicted thiol pKa for C97 increases from 
6.33 to 12.21 following K101 acetylation; while the pKa for C111 increases from 6.26 to 
8.23 (Table 3.4.1-2). Higher pKa values do not favour thiolate (-S-) formation, which 
could negatively affect cysteine’s ability to coordinate zinc. The predicted increase in 
thiol pKa for C97 and C111 is also correlated with increased distance to the zinc they 
coordinate. This could be due to weakened interaction between the two.  
 72 
 
 
 
Figure 3.4.1-1 Acetylation of Lys101 effects GSNOR protein structure around the 
structural zinc binding site 
(A) GSNOR is a dimeric protein. Each subunit contains a CxxC motif as part of the 
structural zinc binding site (shown in orange). (B) Average protein structures of 
unmodified wild-type GSNOR (magenta) and K101_acetylated wild-type GSNOR (blue) 
from MD simulations were overlaid for comparison.  
  
A 
B 
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Table 3.4.1-1 Distance (Å) between GSNOR structural Zn and Cys(S) 
Residue GSNOR WT GSNOR K101A GSNOR K101Q GSNOR 
K101Acetylated 
C97 6.41 4.87 6.75 9.20 
C100 10.21 7.35 5.82 5.84 
C103 6.06 12.53 8.39 8.59 
C111 5.44 8.13 10.60 9.81 
 
Table 3.4.1-2 Predicted cysteine thiol pKa 
Residue GSNOR WT GSNOR K101A GSNOR K101Q GSNOR 
K101Acetylated 
C97 6.33 12.78 8.48 12.21 
C100 8.80 6.60 4.96 8.62 
C103 6.43 8.02 7.93 6.42 
C111 6.26 4.00 9.58 8.23 
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 3.4.2 Kinetic parameters of wild-type and mutant GSNOR 
To assess the role of the conserved lysine residue at position 101, site directed 
mutagenesis was performed using human GSNOR (NM_000671.3) as the template. 
Successful mutation from lysine (K) to either alanine (A) or glutamine (Q) was 
confirmed by sequencing. Lysine to alanine substitution removes a positively charged 
side chain, which could affect the protein microenvironment for the cluster of cysteine 
residues (C97, C100, C103 and C111) involved in structural zinc binding. Out of the 
naturally occurring amino acids, the structure of glutamine best resembles that of 
acetylated lysine. Therefore, lysine to glutamine substitution will offer some insight 
regarding the effect of K101 acetylation.  
When kinetic parameters of wild-type and mutant GSNOR were assessed, it was 
determined that wild-type GSNOR exhibits an apparent Km of 30.2 ± 0.89 µM towards 
GSNO and a kcat of 2467 ± 57.9 min
-1 (Figure 3.4.2-1). Both of these values are 
comparable to previously reported Km of 28 µM and kcat of 2640 min
-1 [54]. Catalytic 
efficiency of GSNOR was calculated as kcat / Km. For the wild-type enzyme, catalytic 
efficiency was determined to be 1360000 ± 9900 s-1M-1 (Table 3.4.2).  
GSNOR K101A exhibits an apparent Km of 27.6 ± 1.65 µM towards GSNO and a 
kcat / Km of 1330000 ± 69400 s
-1M-1 (Figure 3.4.2-1, Table 3.4.2). Both of these 
parameters are not significantly different from the wild-type enzyme, indicating that 
K101 is not involved in substrate binding and does not directly participate in catalysis. 
On the other hand, K101Q mutant shows an apparent Km of 29.2 ± 3.18 µM towards 
GSNO and a kcat / Km of 1090000 ± 81600 s
-1M-1 (Figure 3.4.2-1, Table 3.4.2). The 
experimental Km for K101Q is also comparable to wild-type, but catalytic efficiency of 
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this mutant decreased by approximately 20%. Since glutamine was chosen to mimic the 
structure of acetylated lysine, the observed decrease in catalytic efficiency suggests 
acetylation could be involved in the post-translational regulation of GSNOR activity. 
Enzyme activity as a function of cofactor (NADH) concentration was evaluated 
for wild-type and mutant GSNOR (Figure 3.4.2-2). Apparent Km towards NADH was 
determined to be 34.2 ± 2.72 µM for wild-type GSNOR, 41.3 ± 1.31 µM for K101A, and 
35.2 ± 0.81 µM for K101Q. Based on these Km values, it appears the K101A mutant 
displays slightly reduced affinity for NADH. This could be due to some alterations in 
protein structure as a result of the mutation.   
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Figure 3.4.2-1 Michaelis-Menten kinetics of wild-type and mutant GSNOR 
Initial reaction rates of wild-type GSNOR (WT), GSNOR K101A (K101A) and GSNOR 
K101Q (K101Q) were determined by monitoring absorbance decrease at 340 nm. 
Various GSNO concentrations (ranging from 0 µM to approximately 400 µM) were used. 
Each reaction contains 80 µM NADH and is initiated by the addition of 2 µg of enzyme. 
PBS (pH 7.4) was used as the reaction buffer. Error bars represent standard deviation 
(n=3).  
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Figure 3.4.2-2 GSNOR activity as a function of cofactor concentration  
Initial reaction rates of wild-type GSNOR (WT), GSNOR K101A (K101A) and GSNOR 
K101Q (K101Q) were determined by monitoring absorbance decrease at 340 nm. Each 
reaction contains 200 µM GSNO and various concentrations of NADH (ranging from 0 
to 200 µM). Reaction is initiated by the addition of 2 µg of enzyme. Error bars represent 
standard deviation (n=3). 
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Table 3.4.2 Kinetic parameters of wild-type and mutant GSNOR 
 Wild-type GSNOR 
                                             % of WT 
Km
GSNO (µM) 30.2 ± 0.89 100 ± 3.0 
Km
NADH (µM) 34.2 ± 2.72 100 ± 7.9 
kcat (min
-1) 2468 ± 57.9 100 ± 2.3 
kcat / Km (x 10
3 s-1 M-1) 1360 ± 9.9 100 ± 0.7 
 GSNOR K101A 
                                             % of WT 
Km
GSNO (µM) 27.6 ± 1.65 92 ± 5.5 
Km
NADH (µM) 41.3 ± 1.3 121 ± 3.8* 
kcat (min
-1) 2205 ± 18.2 89 ± 0.7* 
kcat / Km (x 10
3 s-1 M-1) 1330 ± 69.4 98 ± 5.1 
 GSNOR K101Q 
                                             % of WT 
Km
GSNO (µM) 29.2 ± 3.18 97 ± 10.5 
Km
NADH (µM) 35.2 ± 0.81 103 ± 2.4 
kcat (min
-1) 1893 ± 62.1 77 ± 2.5* 
kcat / Km (x 10
3 s-1 M-1) 1090 ± 81.6 80 ± 6.0* 
       Values given as mean ± SD 
         *statistically significant (p < 0.05) 
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 3.4.3 Chemical acetylation of GSNOR 
Lysine acetylation was discovered more than 50 years ago on N-terminal tails of nuclear 
histone proteins [215, 216]. Since then, a large number of non-histone proteins have been 
shown to be regulated by transient Nε-acetylation on select lysine residues [214, 217]. 
Previous findings in our lab suggest acetylation of the CxxC motif flanking lysine in PDI 
affects its enzyme activity. From the previous section, we observed a decrease in GSNOR 
catalytic efficiency when its CxxC flanking lysine was mutated to glutamine, suggesting 
lysine modification may be involved in the regulation of GSNOR activity. In this section, 
in vitro acetylation was performed on wild-type GSNOR and GSNOR K101A using 
acetic anhydride. It is important to point out that this chemical acetylation method is not 
specific as acetic anhydride could also modify amino acid residues other than lysine, such 
as serine and threonine. As a result, caution must be exercised when interpreting 
experimental findings. The rationale behind this set of experiment is if acetylation of 
K101 affects GSNOR activity, then this effect should not be observed in the K101A 
mutant. 
First, immunoblots were produced to verify lysine residues were acetylated. For 
both wild-type GSNOR and K101A, treatment with 20 mM acetic anhydride results in 
strong signals when probed with anti-acetyl-lysine antibody (Figure 3.4.3-1 A). 
Chemical acetylation appears to be correlated with decreases in enzyme activity for both 
wild-type (~50% reduction) and alanine mutant (~45% reduction). Due to its reactivity, 
using acetic anhydride to study lysine acetylation has some limitations. For example, 
residues other than lysine may also become modified; and we cannot control which lysine 
residue gets acetylated. Despite these drawbacks, the observed reduction in GSNOR 
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activity following acetic anhydride treatment provides promising preliminary data for 
acetylation mediated down regulation of GSNOR activity. Methanol control (GSNOR 
treated with 2% methanol, without acetic anhydride) is included for comparison since 
acetic anhydride stock solution is prepared using methanol. Surprisingly, K101A exhibits 
~25% reduction in activity when treated with methanol while wild-type GSNOR is 
unaffected (Figure 3.4.3-1 B). The underlying cause for this differential response is 
currently unknown. From computational predictions, we know that K101 mutation is 
associated with alterations in cysteine thiol pKa and protein structure in the vicinity of the 
structural zinc binding site. However, causal relationship between these predicted 
changes and enzyme’s susceptibility towards methanol-induced effects has yet to be 
established. As a solvent, methanol does not have the same hydrogen bonding capacity as 
water. This may perturb protein-solvent hydrogen bond network, thus affecting dynamic 
properties of GSNOR. Differential response to methanol suggests even though kinetic 
parameters were not dramatically different between wild-type GSNOR and K101A, some 
other property of the enzyme must have been altered in the K to A mutant in order to 
elicit this response.  
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Figure 3.4.3-1 Effect of chemical acetylation on GSNOR activity  
Chemical acetylation of wild-type GSNOR and GSNOR K101A was performed using 
acetic anhydride. (A) Samples were run on SDS-PAGE gels and transferred to PVDF. 
Membranes were probed with anti-acetyl-lysine and anti-His antibodies. (B) Enzyme 
activity was measured as rate of absorbance decrease at 340 nm. Each reaction contains 
80 µM NADH and 200 µM GSNO. Initial reaction rates are graphed as percentage of the 
no treatment control group. Error bars represent standard deviation (n=4). *statistically 
different from no treatment control. **statistically different from no treatment control and 
methanol control.  
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 3.4.4 In vitro S-nitrosation studies 
Earlier this year, Guerra et al. predicted potential S-nitrosation sites within GSNOR using 
the software GPS-SNO and demonstrated S-nitrosation decreases enzyme activity in vitro 
[218]. The group further suggested GSNOR can be S-nitrosated by its own substrate 
GSNO and the transient down-regulation of activity permits robust nitric oxide signaling 
[218]. Inhibition of enzyme activity by its own substrate seems paradoxical. This 
signaling model proposed by Guerra et al., coupled with computationally predicted 
cysteine thiol pKa changes following K101 mutation/modification, prompted us to 
investigate whether GSNOR activity can be regulated by S-nitrosation; and whether 
K101 mutation renders any of the zinc-coordinating cysteines more susceptible to 
oxidation.  
For this purpose, both wild-type GSNOR and K101A mutant were treated with 
0.5 mM GSNO for 30 minutes before activities were assayed. Contrary to results 
published by Guerra and colleagues, GSNO pre-treatment did not have any observable 
effect on enzyme activity (Figure 3.4.4-1); suggesting either GSNOR is not modified by 
its substrate GSNO, or modification has no effect on enzyme activity. To complement 
this finding, biotin-switch or mass spectrometry should be performed to assess the S-
nitrosation status of GSNOR following treatment. Different S-nitrosating agents can also 
be explored since protein S-nitrosation occurs via multiple mechanisms.  
Similarly, treating GSNOR K101A with 0.5 mM GSNO did not effect enzyme 
activity; demonstrating mutation of K101 did not make C97, C100, C103 or C111 more 
susceptible to S-nitrosation despite predicted changes in pKa values. In this case, it is 
highly likely that these 4 cysteine residues are not modified since modification would 
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affect their ability to coordinate zinc, which would translate into significant attenuation of 
enzyme activity. This finding is not unexpected as structural cysteine-zinc complexes are 
usually chemically inert [219, 220]. 
GSNOR is a cysteine-rich protein. Human GSNOR contains a total of 15 cysteine 
residues, 6 of which are involved in zinc binding. At the moment, not much is known 
regarding the chemical reactivity of these residues and whether reversible S-nitrosation is 
one of the mechanisms regulating GSNOR activity. Contrary to recently published 
findings, our results show GSNO pre-treatment does not have any effect on GSNOR 
activity. Additional research in this area is needed to address this discrepancy.  
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Figure 3.4.4-1 GSNO pre-treatment does not affect GSNOR activity 
(A) Wild-type GSNOR and (B) GSNOR K101A are treated with 0.5 mM GSNO for 30 
minutes. Unreacted GSNO is removed using Zeba desalting columns. Enzyme activities 
at various GSNO concentrations are assayed by monitoring the decrease in absorbance at 
340 nm. Each reaction contains 200 µM NADH and is initiated by the addition of 2 µg of 
either wild-type or mutant GSNOR. Error bars represent standard deviation (n=3). 
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 3.4.5 Potential allosteric GSNO binding site and implications for the regulation 
of GSNOR activity 
When looking at GSNOR activity as a function of GSNO concentration, the shape of the 
Michaelis-Menten curve caught our attention. It appears to deviate from the classical 
hyperbola and exhibits increased response to substrate at low concentrations. This let us 
to speculate perhaps GSNOR could be rapidly activated by some factor. In addition, 
semi-logarithmic transformation produced an asymmetrical S-curve (Figure 3.4.5-1 A), 
which is characteristic of enzymes that do not conform to simple kinetics [221].  Hill plot 
was also constructed to determine cooperativity (Figure 3.4.5-1 B). The Hill coefficient 
of GSNOR (calculated as slope of the best fit line) was greater than 1, which indicates the 
existence of some form of positive cooperation. Upon further investigation, 
computational docking results suggest GSNOR may have an allosteric binding site for 
GSNO near the structural zinc domain (Figure 3.4.5-3 A). MD simulations show 
consistent interaction between GSNO and this putative allosteric region, which brings 
forth the possibility that GSNO binding to this site could affect the activity of GSNOR. 
Based on this model, Asn184 and Gly320 appear to interact with GSNO directly; while 
Lys187 and Lys322 interacts indirectly through the solvent network of hydrogen bonds 
(Figure 3.4.5-3 B). Docking scores, which is used to predict binding affinity, also 
support the existence of an allosteric binding site for GSNO. Specifically, GSNO binding 
to the known active site exhibits a score of -8.60; while GSNO binding to the putative 
allosteric site has a score of -10.4 (low scores indicate stable systems and are associated 
with favorable interactions.)  
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 Our hypothesis of allosteric regulation was tested using the fluorogenic substrate 
OAbz-GSNO. GSNOR-mediated reduction of OAbz-GSNO was examined in the 
absence, as well as in the presence, of GSNO. Results indicate including GSNO in the 
reaction leads to enhanced OAbz-GSNO reduction, as evidenced by higher rates of 
fluorescence increase (Figure 3.4.5-2). On the other hand, OAbz-GSNO fluorescence is 
not affected by GSNO alone. Based on these observations, we propose GSNO binding to 
the allosteric site enhances GSNOR activity.  
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Figure 3.4.5-1 Logarithmic plots of GSNOR kinetics 
Initial reaction rates of wild-type GSNOR are determined by monitoring absorbance 
decrease at 340 nm. Each reaction contains 80 µM NADH and is initiated by the addition 
of 2 µg enzyme. (A) Semi-logarithmic plot. (B) Hill plot.  
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Figure 3.4.5-2 GSNO enhances GSNOR-mediated reduction of OAbz-GSNO 
GSNOR activity is measured by monitoring fluorescence increase (excitation at 312 nm, 
emission at 415 nm) due to OAbz-GSNO reduction in the absence of GSNO (circles) and 
in the presence of 40 µM GSNO (diamonds). Each reaction contains 120 µM NADH and 
various concentrations of OAb-GSNO. PBS is used as the reaction buffer. Reaction is 
initiated by the addition of 2 µg of wild-type GSNOR. Error bars represent standard 
deviation (n=3). 
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Figure 3.4.5-3 Putative allosteric GSNO binding site 
High resolution (1.9 Å) X-ray crystal structure of GSNOR from Homo sapiens (PDB ID: 
3QJ5) was used as the base structure for GSNO docking. (A) Putative allosteric GSNO 
binding site is near the structural zinc domain. (B) Predicted interactions between GSNO 
and GSNOR based on the average structure from MD simulations.  
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3.5 Conclusion 
This chapter focuses on kinetic evaluation of GSNOR activity to identify potential 
mechanisms of regulation. First, the role of CxxC flanking K101 was assessed by site-
directed mutagenesis. Results show mutation of K101 to glutamine leads to 
approximately 20% reduction in catalytic efficiency. Since the structure of glutamine is 
similar to the structure of acetylated lysine, K101 acetylation may represent a post-
translational modification involved in the down-regulation of GSNOR activity. Chemical 
acetylation using acetic anhydride also results in decreased enzyme activity. This project 
will be carried forward. In vitro acetylation using recombinant acetyltransferase and mass 
spectrometry will be performed to provide unambiguous evidence regarding the site of 
lysine acetylation and its effect on GSNOR activity.   
Contrary to previously proposed model that S-nitrosation mediated by GSNO 
attenuates GSNOR activity, treatment with 0.5 mM GSNO did not have any effect on 
enzyme activity for both the wild-type and K101A mutant. Instead, our findings suggest a 
different mode of regulation, in which GSNOR activity is enhanced when GSNO binds to 
an allosteric site. This proposed mechanism would allow GSNOR to exhibit greater 
activity when substrate is abundant, effectively restoring cellular homeostasis.  
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CHAPTER 4 
Functional Aspects of Neutral Sphingomyelinase II 
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4.1 Introduction 
Sphingolipids are major constituents of the plasma membrane in eukaryotic cells. This 
class of lipids typically consists of a sphingosine backbone, a long chain fatty acid, and a 
variable polar head group. Originally considered to serve only structural roles, these 
lipids are now recognized as important participants in a wide range of signal transduction 
pathways [222, 223]. In particular, sphingomyelin-based pathways have received 
considerable attention in recent years. Structurally, sphingomyelin (SM) has a polar 
phosphorylcholine head group and the composition of the long chain fatty acid varies 
from tissue to tissue and can be either saturated or mono-unsaturated with 14 to 24 
carbons [224, 225]. Results based on cell fractionation studies and degradation 
experiments suggest that more than half of the cellular SM mass is confined to the plasma 
membrane [226]. The exact percentage may vary from one cell type to another, though it 
has been reported that cells with extensive plasma membrane recycling have a larger 
fraction of SM in intracellular compartments [227]. 
SM’s role in signaling is multifaceted. Its hydrolysis generates bioactive 
ceramide, a lipid second messenger molecule capable of modulating cellular events such 
as cell cycle arrest, differentiation, inflammation and apoptosis [132-134]. SM hydrolysis 
is specifically catalyzed by the family of enzymes known as sphingomyelinase (EC 
3.1.4.12). This enzyme family is further divided into three groups (acid, neutral and 
alkaline) based on their distinct catalytic pH optimum. Of the different forms of 
sphingomyelinases identified and studied to date, the magnesium-dependent neutral 
sphingomyelinase II (NSMase II) has emerged as the predominant sphingomyelinase 
implicated in a diverse set of cellular functions and disease pathologies [180, 228]. 
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During recent years, a large number of studies have identified NSMase II as a mediator of 
cellular stress response, mainly through the production of ceramide. Exposures to 
oxidative stress [160, 163], pro-inflammatory cytokines [169], and anti-cancer 
compounds [187, 229] can up-regulate NSMase II expression and activity, which 
increases cellular ceramide levels to signal apoptosis or senescence. 
In addition to ceramide generation, NSMase II catalyzed SM degradation may 
also affect the formation of lipid rafts within the plasma membrane. Lipid rafts are 
ordered microdomains enriched in SM and cholesterol. These microdomains are 
detergent resistant and have been proposed to serve as platforms for the attachment of 
different proteins involved in signaling [230]. Specific proteins can be selectively 
included or excluded from these laterally organized microdomains, thus facilitating 
various signaling events [231, 232]. A consistent ratio between SM and cholesterol needs 
to be maintained in the plasma membrane to support lipid raft formation, and there is 
evidence indicating plasma membrane SM and cholesterol levels are coordinately 
regulated [233]. For example, reduction of SM level by the addition of purified bacterial 
sphingomyelinase to cultured cells decreases membrane’s ability to solubilize cholesterol, 
which leads to increased cholesterol esterification and transport to intracellular sites, as 
well as down-regulation of cholesterol de novo synthesis [234-236]. Although NSMase II 
was not directly implicated in these studies, it is reasonable to hypothesize that stress 
induced NSMase II activation could also affect plasma membrane cholesterol content and 
lipid raft formation.  
Cortisol is the principle glucocorticoid hormone in humans. It is produced by the 
adrenal cortex and released into circulation according to a distinct circadian pattern [237]. 
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Disruptions to this daily rhythm have been observed in patients with breast and ovarian 
cancer [238]. In this chapter, cortisol exposure was used as a stressor and its effect on 
NSMase II expression and activity were assessed. The ability of NSMase II to modulate 
plasma membrane cholesterol content was also explored.  
The regulation of NSMase II activity is not well understood and contradictory 
findings have been reported. For instance, while Liu and Hannun observed physiological 
concentrations of GSH can effectively inhibit NSMase II activity [188];  Dotson et al. 
reported increases in activity in response to reducing agents, such as GSH and 2-
mercaptoethanol [239]. Despite these seemingly contradictory findings, cellular redox 
environment clearly has an effect on NSMase II activity. In addition, human NSMase II 
contains a total of 23 cysteine residues, for which the redox sensitivity has not been fully 
assessed. Since our lab is interested in the post-translational modification S-nitrosation, 
the last part of this project will focus on in vitro NSMase II activity in response to GSNO 
treatment.  
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4.2 Material 
Ampicillin (A0166), cortisol (H0888), DNase I (DN25), imidazole (I0125), isopropyl β-
D-1-thiogalactopyranoside (I6758), lysozyme (L7651), magnesium chloride (M2570), 
phenylmethylsulfonyl fluoride (7626), and Triton X-100 (T9284) were purchased from 
Sigma-Aldrich. Sodium chloride (S2830) was purchased from ACP Chemicals. 
Kanamycin (BP906) and Tris-HCl (BP153) were purchased from Fisher Scientific. 
Dithiothreitol (100597) was purchased from MP Biomedicals. Fluoromount G (0100-01) 
was purchased from Southern Biotech.  
4.3 Methods 
 4.3.1 Cell culture 
Triple negative breast cancer cells (HTB 126) were purchased from ATCC and 
maintained in DMEM high-glucose medium (HyClone SH30022.01) supplemented with 
10% fetal bovine serum (GIBCO 12483), 100 μg/mL streptomycin and 100 U/mL 
penicillin. Human embryonic kidney cells (HEK 293) were also obtained from ATCC 
and cultured in DMEM nutrient mixture F-12 Ham (Sigma D6421) supplemented with 
10% fetal bovine serum, 100 μg/mL streptomycin and 100 U/mL penicillin. All cells 
were maintained in a humidiﬁed incubator at 37°C with 5% CO2. For regular 
maintenance, cells were sub-cultured when confluency reached approximately 85%. 
 4.3.2 Cortisol treatment 
Cortisol stock solution (100 mM) was prepared in dimethyl sulfoxide (DMSO). Cultured 
HTB 126 cells were treated with cortisol at a final concentration of 80 µM for 24 hours 
before analysis. Cells mock-treated with DMSO were used as controls.  
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 4.3.3 NSMase II over-expression 
HEK 293 cells were grown in 6-well plates or on 4-chamber slides. Transient transfection 
was performed using pCMV-SPORT6 NSMase II expression plasmid (Open Biosystems 
6399438) with Lipofectamine LTX reagent (Invitrogen A12621) according to 
manufacturer’s recommendations. Transfection was carried out for 36 hours prior to 
subsequent analysis. Success of transfection was assessed using immunoblots, as well as 
indirect immunofluorescence.  
 4.3.4 Immunofluorescence 
Following cortisol treatment or transfection, cells were fixed with 2% paraformaldehyde 
for 1 hour at room temperature. After paraformaldehyde was removed, cells were washed 
three times using PBS and blocked with 5% BSA for 1 hour. Then, blocking buffer was 
removed and cells were incubated with rabbit anti-NSMase II antibody (1:100; Santa 
Cruz Biotechnology sc-67305) for 2 hours. After washing with PBS three times, cells 
were further incubated with goat anti-rabbit Alexa 488 (1:500; Invitrogen A-11008) for 1 
hour. To visualize the nuclei, cells were stained with either Hoechst 33342 for 5 minutes, 
or propidium iodide for 15 minutes. Finally, cells were washed 3 times with PBS and 
mounted using Fluoromount G. Images were taken on a Leica microscope using 40X oil 
objective. 
  4.3.5 PFO-D4-GFP_GST expression and purification 
The construct PFO-D4-GFP_GST was kindly provided by Dr. Irina Pikuleva from Case 
Western Reserve University. This construct was transformed into BL21(DE3) E.coli 
(New England BioLabs C2527) using standard heat shock method. Ampicillin at a 
concentration of 100 µg/mL was used for selection. When the bacterial culture has 
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reached an optical density of approximately 0.6, PFO-D4-GFP_GST expression was 
induced by the addition of IPTG to a final concentration of 1 mM. The induced culture 
was grown for an additional 5 hours at 37°C before cells were harvested by centrifugation 
(4000 g, 30 minutes, 4°C). Following centrifugation, the bacterial cell pellet was 
resuspended in lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM PMSF, 1% 
Triton X100, 1 mg/mL DNase I and 10 mg/mL lysozyme). Crude lysate was further lysed 
by pulse sonication (20 seconds on, 20 seconds off, 10 cycles). Another round of 
centrifugation (11300 g, 30 minutes, 4°C) was performed and the clarified lysate was 
applied to a glutathione sepharose 4B column pre-equilibrated with wash buffer (50 mM 
Tris-HCl pH 8, 150 mM NaCl). After the lysate has passed through the column, 5 column 
volumes of wash buffer was used to remove non-bound sample components followed by 
elution using wash buffer supplemented with 10 mM GSH. Finally, eluted PFO-D4-
GFP_GST was concentrated and buffer exchanged into PBS pH 7.4 using Amicon 
centrifugal filter (Millipore UFC903008) before storage at -80°C. 
 4.3.6 PFO-D4-GFP staining 
HEK 293 cells were grown on 4-chamber slides. Following transfection, cells were fixed 
with 2% paraformaldehyde for 1 hour at room temperature. Fixed cells were then washed 
3 times using PBS and stained with PFO-D4-GFP_GST (1 mM) for 30 minutes. To 
visualize the nuclei, Hoechst 33342 stain was added for 5 minutes. Finally, cells were 
washed 3 times with PBS, mounted using Fluoromount G and imaged on a Leica 
microscope with 40X oil objective.  
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 4.3.7 SMPD3 sub-cloning 
Human full length SMPD3, which encodes NSMase II, was sub-cloned into bacterial 
expression vector pET28b using Cold Fusion Cloning Kit (MJS BioLynx Inc. 
SYMC010A1). The cloning strategy involves direct ligation of PCR amplified gene of 
interest to the linearized destination vector. Primers used for PCR were designed 
according to manufacturer’s guidelines and contain bases complimentary to the gene of 
interest, as well as bases complementary to the linearized destination vector. The 
following primers were used for SMPD3 sub-cloning:  
Forward 5’ – GTG CCG CGC GGC AGC CAT ATG GTT TTG TAC ACG ACC CCC – 3’ 
Reverse 5’ – GTG GTG GTG GTG GTG CTC GAG TGC CTC CTC CTC CCC CGA AGA C– 3’ 
Prior to ligation, destination vector pET28b was linearized by digestion with restriction 
enzymes NdeI and XhoI; and both PCR amplified SMPD3 and linearized pET28b were 
gel purified (Qiagen 20021). Ligation reaction was performed following manufacturer’s 
protocol and the ligated plasmid DNA was transformed directly into chemically 
competent DH5 E.coli (New England BioLabs C2987). Colonies were screened using 
diagnostic restriction enzyme digest and partial sequencing (Robart’s Research Institute). 
 4.3.8 NSMase II expression and purification 
pET28b_SMPD3 was transformed into BL21(DE3) E.coli (New England BioLabs 
C2527). This plasmid encodes full length human NSMase II with two terminal 6X-
Histidine tags to facilitate purification. A single colony from the transformation plate was 
inoculated into 25 mL of 2X YT medium containing 50 µg/mL kanamycin and the 
culture was grown overnight at 37°C with shaking. This overnight culture was then used 
to inoculate 1L of 2X YT medium containing 50 µg/mL kanamycin and the culture was 
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again grown at 37°C until optical density reached approximately 0.6. Protein expression 
was induced by the addition of IPTG to a final concentration of 0.4 mM. The induced 
culture was grown for an additional 24 hours at room temperature before cells were 
harvested by centrifugation (4000 g, 30 minutes, 4°C). Following centrifugation, the 
bacterial cell pellet was resuspended in lysis buffer (50 mM Tris-HCl pH 7.5, 300 mM 
NaCl, 5 mM MgCl2, 0.2% Triton X100, 1 mM DTT, 1 mM PMSF, 50 µg/mL DNase I 
and 100 µg/mL lysozyme). The crude lysate was incubated on ice for 30 minutes and 
further lysed by pulse sonication (20 seconds on, 20 seconds off, 30 cycles). Another 
round of centrifugation (11300 g, 30 minutes, 4°C) was performed and the clarified lysate 
was applied to nickel affinity (Sigma P6611) column pre-equilibrated with lysis buffer. 
Nickel affinity purification was performed strictly following manufacturer’s protocol 
published by Sigma Aldrich with some modifications in buffer composition. The wash 
buffer contains 50 mM Tris-HCl pH 7.5, 300 mM NaCl, 5 mM MgCl2, 0.2% Triton 
X100, and 15 mM imidazole while the elution buffer contains 50 mM Tris-HCl pH 7.5, 
300 mM NaCl, 5 mM MgCl2, 0.2% Triton X100, and 300 mM imidazole. Eluted protein 
was buffer exchanged into storage solution (50 mM Tris-HCl pH 7.5, 5 mM MgCl2 and 
0.2% Triton X100) using Amicon centrifugal filter (Millipore UFC903008) before 
storage at -80°C. 
 4.3.9 NSMase Activity assay 
NSMase activity was assessed using Amplex Red Sphingomyelinase Assay kit 
(Invitrogen A12220) in accordance with manufacturer’s published protocol. In this 
fluorescence-based assay, NSMase activity is monitored indirectly using Amplex Red 
reagent, which is a fluorogenic probe for H2O2. Briefly, NSMase catalyzed SM 
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hydrolysis produces ceramide and phosphorylcholine. Then, phosphorylcholine is acted 
upon by alkaline phosphatase and choline oxidase to produce H2O2, which reacts with 
Amplex Red in the presence of horseradish peroxidase to generate a highly fluorescent 
end product.  
 4.3.10 Mass spectrometry 
Purified NSMase II (1 mg/mL) was treated with 0.5 mM GSNO for 30 minutes in the 
dark. Enzyme mock-treated with PBS was used as the control. Following GSNO 
treatment, free –SH groups in NSMase II were labeled using 20 mM iodoacetamide (2 
hours, room temperature, in the dark). Excess iodoacetamide was removed by passing the 
samples through desalting columns (Fisher Scientific 89882). Then, 10 mM sinapinic 
acid was used to reduce S-nitrosated thiols (1 hour, room temperature), followed by 20 
mM N-ethylmaleimide treatment to label previously S-nitrosated thiols (50°C, 30 
minutes). After labeling, excess N-ethylmaleimide was removed and samples were 
buffered exchanged into 50 mM ammonium bicarbonate (pH8.0) using desalting 
columns. Finally, protein samples were digested with trypsin (Promega V511A) 
overnight at 37°C (1:20 trypsin to protein ratio). C18 Zip Tips (Millipore ZTC18S096) 
were used to clean up the tryptic peptides before MS analysis.  
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4.4 Results and Discussion 
 4.4.1 Effect of cortisol treatment on NSMase II expression and activity 
NSMase II catalyzed ceramide generation is involved in cellular stress response. 
Stressors such as hydrogen peroxide can selectively up-regulate the expression or activity 
of NSMase II; concomitant increase in ceramide levels then mediates the appropriate 
stress response (e.g., cell cycle arrest, apoptosis) [228]. In this section, cortisol exposure 
was used as the stressor and its effect on endogenous NSMase II expression and activity 
was investigated. Triple negative breast cancer cells (HTB 126) were exposed to 80 µM 
cortisol for 24 hours. Following treatment, cell viability was assessed using Trypan Blue. 
Results show cortisol exposure does not negatively affect viability. Both control and 
treated cells exhibit similar viability at approximately 95% (Figure 4.4.1-1 A). NSMaseII 
expression level and activity were determined using immunofluorescence and Amplex 
Red enzyme-coupled assay, respectively. In both cases, no significant difference was 
observed between DMSO-treated control cells and cortisol-treated cells (Figure 4.4.1-1 
B-D). However, cortisol-treated cells are larger in size than their control counterparts 
(Figure 4.4.1-1 B). Although the underlying mechanism has not yet been determined, it 
is possible that cortisol could play a role in promoting cell growth or inhibiting cell 
division. 
 To explore the reason for lack of NSMase II activation in response to cortisol, the 
following factor should be considered: 
1. HTB126 is a triple negative breast cancer cell line. Its basal level of NSMase II 
expression and activity needs to be carefully evaluated. For this project, Amplex Red 
assay kit was used to estimate NSMase II activity. This method is indirect and measures 
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enzyme coupled hydrogen peroxide generation. Although this assay works well with 
purified NSMase II in vitro, it may not be suitable for complex cellular lysate samples 
since enzymes/molecules within the lysate could affect hydrogen peroxide levels. 
Measurement of cellular ceramide levels will complement our NSMase II activity results.  
2. Acute stress and chronic stress may elicit different responses. Varying the length of 
cortisol exposure will offer insight in this area. 
3. In literature, NSMase II was almost always over-expressed before cells were exposed 
to stimuli/stressor; whereas we looked at endogenous NSMase II. Different experiment 
methods will affect results obtained.  
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Figure 4.4.1-1 Effect of cortisol treatment on NSMase II expression and activity 
HTB 126 cells were treated with 80 µM cortisol for 24 hours. (A) Viability was assessed 
using trypan blue exclusion assay. Percent viable is shown as mean ± SD (n=4). (B) After 
cortisol treatment, cells were fixed using 2% paraformaldehyde, stained with anti-
NSMase II antibody, followed by Alexa 488 conjugated secondary antibody. Nuclei were 
visualized using propidium iodide. 3 representative images were shown from 3 
independent experiments. Scale bar = 25 µm. (C) Fluorescence from ~50 cells were 
quantified using ImageJ as integrated density. Cumulative results were shown as % of 
control. Error bars represent SD. (D) NSMase activity from cell lysate was estimated 
using the Amplex Red activity assay kit. Results are shown as % of control. Error bars 
represent SD. 
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 4.4.2 NSMase II over-expression is associated with decreases in plasma 
membrane cholesterol content 
Within the plasma membrane, SM preferentially associates with cholesterol to form 
ordered microdomains [240] and evidence exist for the coordinated regulation of SM and 
cholesterol levels [233]. To determine whether plasma membrane cholesterol levels can 
be indirectly regulated by NSMase II activity, transient transfection was performed to 
over-express untagged NSMase II in HEK 293 cells. Transfection success was confirmed 
using immunoblotting (Figure 4.4.2-1 A). Activity assay was performed and more than 
2-fold increase in activity was observed following transfection (Figure 4.4.2-1 B), 
demonstrating that over-expressed NSMase II is active. PFO-D4-GFP_GST was used to 
label plasma membrane cholesterol and imaging results indicated an inverse relationship 
between NSMase II expression/activity and plasma membrane cholesterol content 
(Figure 4.4.2-2). This demonstrates modulation of NSMase II activity is accompanied by 
alterations in plasma membrane cholesterol level; which is suggestive that in addition to 
ceramide generation, NSMase II may also elicit physiological responses by affecting lipid 
raft formation.    
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Figure 4.4.2-1 Over-expression of NSMase II is correlated with increased activity 
HEK 293 cells were transiently transfected to over-express NSMase II. (A) 36 hours after 
transfection, cells were harvested and lysed using non-denaturing lysis buffer. Protein 
concentrations were determined for each sample and equal amounts were run on SDS-
PAGE. Following separation, proteins were transferred to PVDF membrane and blotted 
for NSMase II. (B) NSMase activity from cell lysate was estimated using Amplex Red 
NSMase activity assay kit. Results are shown as % of control. Error bars represent SD. 
*Statistically different from control (p < 0.05).  
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Figure 4.4.2-2 NSMase II over-expression is correlated with decreased plasma 
membrane cholesterol level 
HEK 293 cells were plated on 4 chamber slides and transiently transfected to over-
express NSMase II. (A) 36 hours after transfection, cells were fixed using 2% 
paraformaldehyde, stained with anti-NSMase II antibody, followed by Alexa 488 
conjugated secondary antibody. Nuclei were visualized using Hoechst 33342 stain. 3 
representative images were shown from 3 independent experiments. Scale bar = 25 µm. 
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(B) Fluorescence from ~50 cells were quantified using ImageJ as integrated density. 
Cumulative results were shown as % of control. Error bars represent SD. (C) Cells were 
fixed using 2% paraformaldehyde and labeled with the plasma membrane cholesterol 
probe PFO-D4-GFP_GST. Nuclei were visualized using Hoechst 33342 stain. 3 
representative images were shown from 3 independent experiments. Scale bar = 25 µm. 
(B) Fluorescence from ~50 cells were quantified using ImageJ as integrated density. 
Cumulative results were shown as % of control. Error bars represent SD. *Statistically 
different from control (p < 0.05). 
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 4.4.3 S-nitrosation mediated down-regulation of NSMase II activity 
Exposure to cigarette smoke and hydrogen peroxide has been shown to lead to NSMase II 
activation, which augments ceramide mediated apoptosis in bronchial epithelial cells 
[160]. Interestingly, when we treated HTB 126 cells with hydrogen peroxide, NSMase II 
activity decreased by approximately 40% and cell viability was not negatively affected 
(Figure 4.4.3-1). This led us to speculate whether NSMase II activity is selectively 
down-regulated in cancer cells in order to evade ceramide induced apoptosis. Since 
human NSMase II is a redox-sensitive enzyme with a total of 23 cysteine residues, S-
nitrosation became the candidate modification under investigation. Currently, reactivity 
of these cysteine residues, as well as their susceptibility towards modification, are not 
fully understood. We purified recombinant NSMase II from bacteria and our enzyme 
preparation is catalytically functional (Figure 4.4.3-2 A). Incubation with GSNO 
decreases NSMase II activity in a concentration dependent manner (Figure 4.4.3-2 B), 
suggesting potential regulation of enzyme activity through protein S-nitrosation.   
Numerous attempts were made to identify candidate S-nitrosation sites using mass 
spectrometry. This has proven to be challenging due to low sequence coverage and low 
signal intensity. Very few peptides were detected and none of them contain cysteine 
residues (Table 4.4.3). This might be due to inherent properties of membrane proteins 
and peptide enrichment is likely needed in order to achieve better sequence coverage.  
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Figure 4.4.3-1 Effect of hydrogen peroxide treatment on HTB 126 cells 
HTB 126 cells were treated with hydrogen peroxide in complete cell culture medium for 
30 minuts. (A) Viability was assessed using Trypan Blue. (B) Following treatment, 
culture medium was removed and cells were washed 3 times with DPBS. Lysates were 
prepared by homogenization and total protein concentration was determined using 
Bradford reagent. NSMase II activity from cellular lysates (protein concentrations were 
equalized) was assayed using Amplex Red assay kit. Error bars represent SD (n=3). 
*statistically different from control. 
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Figure 4.4.3-2 In vitro GSNO treatment attenuates NSMase II activity 
Recombinant NSMase II was purified from E.coli. (A) NSMase II activity from purified 
enzyme preparation was assayed using Amplex Red assay kit. (B) Purified NSMase II 
was treated with various concentrations of GSNO for 30 minutes. Enzyme activity was 
then assessed using Amplex Red assay kit. Error bars represent SD. 
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Figure 4.4.3-3 MALDI-MS spectrum of NSMase II tryptic digest 
Purified NSMase II is treated with 0.5 mM GSNO and differentially labeled with 
iodoacetamide and N-ethylmaleimide. Sample is digested with trypsin and analyzed using 
Applied Biosystems Voyager DE-Pro Mass Spectrometer. Spectra peaks were manually 
compared to theoretical digest masses predicted by UCSF Protein Prospector.  
 
Table 4.4.3 NSMase II peptides identified by MALDI-MS 
Theoretical Mass 
(m/z) 
Observed Mass 
(m/z) 
Peptide Sequence 
954.5156 
954.5479 
954.5255 (R)RPYIYSR(L)  
(R)NGAARPQIK(I)  
 
1055.5408 1055.4794 (R)EYLAFPTSK(S)  
 
1074.5538 1074.4829 (K)VLESEEGRR(E) 
 
1176.6120 1176.4709 (R)VNNLFNTQAR(A)  
 
1214.6124 1214.4341 (K)VQVGSTPQDQR(I)  
 
1340.7096 1340.4207 (R)LAASFIPTTYEK(R)  
 
1558.7761 1558.3383 (K)LEQQHSLFTHYR(D) 
 
2161.0268 2160.0500 (R)IGGEEGGRPPEADDPVPGGQAR(N)  
 
2297.0137 2296.9139 (R)GQTPNHNQQDGDSGSLGSPSASR(E) 
 
2997.4800 2996.7330 (K)IYIDSPTNTSISAASFSSLVSPQGGDGVAR(A)  
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4.5 Conclusion 
Cortisol exposure at a concentration of 80 µM led to increases in cell size. However, 
NSMase II expression and activity were not affected. When looking at the relationship 
between NSMase II and plasma membrane cholesterol, it was observed that increased 
NSMase II activity is correlated with decreased cholesterol. This suggests NSMase II 
activity may contribute to the regulation of lipid raft signaling events. In addition, we 
presented evidence that S-nitrosation is potentially involved in the down-regulation of 
NSMase II activity. Further studies will need to be performed to identify specific residues 
involved.   
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CHAPTER 5 
General Conclusion 
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Protein S-nitrosation is the covalent attachment of NO derived nitroso group to reactive 
cysteine thiols. This reversible post-translational modification affects many aspects of 
protein function, such as activity, localization and stability. In the cellular environment, 
S-nitrosated proteins often exist in equilibrium with GSNO via transnitrosation. As a 
result, enzymes with GSNO metabolizing activity can indirectly drive protein 
denitrosation. Multiple enzyme systems have been shown to metabolize GSNO. Of these 
enzymes, GSNOR is the most efficient at removing the NO equivalents stored in GSNO. 
In addition, aberrant GSNOR activity is implicated in a large number of human diseases. 
GSNOR inhibition represents a relatively recent therapeutic approach and the evaluation 
of small molecule inhibitors is an active area of research. Conventionally, GSNOR 
activity is assayed by looking at absorbance decreases at 340 nm, which corresponds to 
NADH and GSNO consumption. While this method is easy to use, its application is 
limited to purified enzyme in vitro. In chapter 2, we reported the synthesis and 
characterization of OAbz-GSNO, a fluorogenic substrate for GSNOR. The fluorescence 
of OAbz-GSNO is enhanced upon reduction of its –SNO moiety; and the rate of 
fluorescence increase is correlated with GSNOR activity. This substrate is membrane 
permeable and can be used to monitor endogenous GSNOR activity in live cells. Overall, 
OAbz-GSNO is the first compound to be reported which can be used to measure GSNOR 
activity, both in vitro and in live cells. This substrate represents an additional tool 
researchers could use to assess the activity of GSNOR.  
It is well-established that GSNOR plays an important role in maintaining SNO 
homeostasis. However, regulation of its activity remains poorly understood. Chapter 3 
focuses on the identification of potential post-translational mechanisms involved in the 
regulation of GSNOR activity. Site-directed mutagenesis and chemical acetylation 
experiments provided evidence that acetylation of Lys101, which is adjacent to the zinc 
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finger motif, may negatively regulate GSNOR activity. Through kinetic and 
computational studies, we also identified a putative allosteric GSNO binding site. Results 
suggest GSNO binding to this allosteric site may enhance GSNOR activity. Our model of 
substrate activation allows GSNOR to exhibit enhanced activity when GSNO is present, 
effectively returning the system to homeostasis. 
NSMase II catalyzes the hydrolysis of sphingomyelin to generate bioactive 
ceramide, a second messenger molecule capable of mediating a variety of cellular events. 
Activation of NSMase II is an important mechanism of cellular stress response. In 
chapter 4, we exposed cultured breast cancer cells to cortisol and observed that this 
treatment did not have any effect on NSMase II expression/activity. Interestingly, 
cortisol-treated cells grew to be much larger in size than their control counterparts. The 
underlying mechanism has yet to be determined. NSMase II over-expression was 
correlated with decreased plasma membrane cholesterol levels. Since cholesterol is an 
important component in the formation of lipid rafts, this finding carries the implication 
that induction of NSMase II not only generates ceramide, but could also affect additional 
signaling pathways mediated through lipid rafts. In vitro treatment with GSNO attenuates 
NSMase II activity, suggesting that protein S-nitrosation may be one of the modifications 
involved in the regulation of NSMase II activity. 
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Appendix A – NMR Characterization 
 
 
Figure A.1 Correlation spectroscopy (COSY) of OAbz-GSNO 
Pooled OAbz-GSNO was lyophilized and re-dissolved in minimum volume D2O. 
Spectrum was collected on a Bruker 500 MHz Avance III spectrometer using a BBFO 
probe. This COSY spectrum was used to assign 1H NMR peaks for OAbz-GSNO.  
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Appendix B – Recombinant Protein Sequence 
 
MGSSHHHHHH SSGLVPRGSH MANEVIKCKA AVAWEAGKPL SIEEIEVAPP 
KAHEVRIKII ATAVCHTDAY TLSGADPEGC FPVILGHEGA GIVESVGEGV 
TKLKAGDTVI PLYIPQCGEC KFCLNPKTNL CQKIRVTQGK GLMPDGTSRF 
TCKGKTILHY MGTSTFSEYT VVADISVAKI DPLAPLDKVC LLGCGISTGY 
GAAVNTAKLE PGSVCAVFGL GGVGLAVIMG CKVAGASRII GVDINKDKFA 
RAKEFGATEC INPQDFSKPI QEVLIEMTDG GVDYSFECIG NVKVMRAALE 
ACHKGWGVSV VVGVAASGEE IATRPFQLVT GRTWKGTAFG GWKSVESVPK 
LVSEYMSKKI KVDEFVTHNL SFDEINKAFE LMHSGKSIRT VVKILEHHHH  
HH* 
 
Figure B.1 Recombinant GSNOR protein sequence  
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MGSSHHHHHH SSGLVPRGSH MVLYTTPFPN SCLSALHCVS WALIFPCYWL 
VDRLAASFIP TTYEKRQRAD DPCCLQLLCT ALFTPIYLAL LVASLPFAFL 
GFLFWSPLQS ARRPYIYSRL EDKGLAGGAA LLSEWKGTGP GKSFCFATAN 
VCLLPDSLAR VNNLFNTQAR AKEIGQRIRN GAARPQIKIY IDSPTNTSIS 
AASFSSLVSP QGGDGVARAV PGSIKRTASV EYKGDGGRHP GDEAANGPAS 
GDPVDSSSPE DACIVRIGGE EGGRPPEADD PVPGGQARNG AGGGPRGQTP 
NHNQQDGDSG SLGSPSASRE SLVKGRAGPD TSASGEPGAN SKLLYKASVV 
KKAAARRRRH PDEAFDHEVS AFFPANLDFL CLQEVFDKRA ATKLKEQLHG 
YFEYILYDVG VYGCQGCCSF KCLNSGLLFA SRYPIMDVAY HCYPNKCNDD 
ALASKGALFL KVQVGSTPQD QRIVGYIACT HLHAPQEDSA IRCGQLDLLQ 
DWLADFRKST SSSSAANPEE LVAFDVVCGD FNFDNCSSDD KLEQQHSLFT 
HYRDPCRLGP GEEKPWAIGT LLDTNGLYDE DVCTPDNLQK VLESEEGRRE 
YLAFPTSKSS GQKGRKELLK GNGRRIDYML HAEEGLCPDW KAEVEEFSFI 
TQLSGLTDHL PVAMRLMVSS GEEEAHHHHH H* 
 
Figure B.2 Recombinant NSMase II protein sequence  
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Appendix C – Protein Purification Gels 
 
                               
Figure C.1 GSNOR and GSNOR K101A protein purification gels 
Following Nickel affinity chromatography and buffer exchange, purified proteins were 
analyzed on 10% SDS-PAGE gels under reducing conditions. Protein bands were 
visualized using Coomassie Brilliant Blue. 
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Figure C.2 GSNOR K101Q protein purification gel 
Following Nickel affinity chromatography and buffer exchange, purified GSNOR K101Q 
was analyzed on 10% SDS-PAGE gel under reducing conditions. Protein bands were 
visualized using Coomassie Brilliant Blue. 
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Figure C.3 NSMase II protein purification gel 
Following Nickel affinity chromatography and buffer exchange, purified NSMase II was 
analyzed on 10% SDS-PAGE gel under reducing conditions. Protein bands were 
visualized using Coomassie Brilliant Blue. 
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